A COMPUTATIONAL BIOLOGY APPROACH TO THE 
ANALYSIS OF COMPLEX PHYSIOLOGY: 
COAGULATION, FIBRINOLYSIS, AND WOUND HEALING by Menke, Nathan
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2010
A COMPUTATIONAL BIOLOGY APPROACH
TO THE ANALYSIS OF COMPLEX
PHYSIOLOGY: COAGULATION,
FIBRINOLYSIS, AND WOUND HEALING
Nathan Menke
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Biochemistry, Biophysics, and Structural Biology Commons
© The Author
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/2093
 
A COMPUTATIONAL BIOLOGY APPROACH TO THE  
ANALYSIS OF COMPLEX PHYSIOLOGY:  
COAGULATION, FIBRINOLYSIS, AND WOUND HEALING 
 
 
 
  
 
 
 
 
 
 
 
Nathan B. Menke               2010 
All Rights Reserved 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A COMPUTATIONAL BIOLOGY APPROACH TO THE  
ANALYSIS OF COMPLEX PHYSIOLOGY:  
COAGULATION, FIBRINOLYSIS, AND WOUND HEALING 
 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
 
 
 
 
 
By  
 
 
Nathan Menke, M.D. 
Doctor of Medicine, The Ohio State University, 2002 
Bachelor of Science, The Ohio State University Biochemistry, 1997 
Bachelor of Science, The Ohio State University Computer and Information Science,1997 
 
 
Director: Robert F. Diegelmann, Ph.D.  
Professor  
Department of Biochemistry and Molecular Biology 
 
 
 
 
 
 
 
 
 
 
Virginia Commonwealth University  
Richmond, Virginia  
May 2010 
 
ii 
 
 
Acknowledgment  
 
The author wishes to express his heartfelt appreciation to several people instrumental in 
the completion of this endeavor.  I would like to thank my wife, Marie, for her love, 
support and patience during the past five years it has taken me to graduate.  I would like 
to thank my parents for their unending love and support.  I would also like to thank Dr. 
Diegelmann for his mentorship and patience during this long journey.  I would like to 
thank Dr. Ward for the inspiration, guidance, and constant encouragement in the pursuit 
of a research career.  Finally, I thank my Ph.D. committee (Drs. Barton, Fang, and 
Witten) for their insight and valuable time committed to this process. 
 
iii 
 
TABLE OF CONTENTS 
 
 
List of Tables  ....................................................................................................................................v 
List of Figures  ...................................................................................................................................vi 
List of Abbreviations  ........................................................................................................................viii 
Abstract  .............................................................................................................................................x 
Introduction  .......................................................................................................................................1 
I.    Complexity Theory  .....................................................................................................................1 
1. Reductionism  ....................................................................................................................1 
2. Definition  ..........................................................................................................................1 
3. Properties ...........................................................................................................................2 
4. Examples  ...........................................................................................................................6 
II. Biologic Complexity  ....................................................................................................................7 
1. Wound Healing  .................................................................................................................7 
2. Coagulation &  Fibrinolysis ...............................................................................................21 
III. Computational Biology  ...............................................................................................................28 
1. Ordinary Differential Equations  ........................................................................................31 
2. Agent Based Modeling  ......................................................................................................33 
Chapter One: An in silico approach to the analysis of acute wound healing ...............................37 
1. Introduction  .......................................................................................................................39 
2. Materials and Methods  ......................................................................................................40 
3. Results  ...............................................................................................................................48 
4. Discussion  .........................................................................................................................54 
Chapter Two: A Computational Model of Coagulation and Fibrinolysis ....................................62 
1. Introduction  .......................................................................................................................63 
2. Materials and Methods  ......................................................................................................67 
3. Results  ...............................................................................................................................73 
4. Discussion  .........................................................................................................................88 
 
iv 
 
Chapter Three: A Computational Analysis of the Synergistic Effect of 
Coagulation Inhibitors on the Generation of Thrombin ..............................................................103 
1. Introduction  .......................................................................................................................103 
2. Materials and Methods  ......................................................................................................111 
3. Results  ...............................................................................................................................113 
4. Discussion  .........................................................................................................................116 
Chapter Four: Future Directions ........................................................................................................122 
1. TIC  ....................................................................................................................................122 
2. DIC  ....................................................................................................................................124 
3. Cardiac Arrest  ...................................................................................................................126 
4. Graphics Processing Unit   .................................................................................................127 
Summary  ...........................................................................................................................................129 
References  .........................................................................................................................................137 
Vita  ....................................................................................................................................................142 
 
v 
 
 
 
 
LIST OF TABLES  
 
 
Table  .................................................................................................................................................Page 
 
1-1.  Baseline parameter values .........................................................................................................59 
 
2-1.  Initiation phase length   .............................................................................................................75 
 
2-2.  Maximum thrombin generation rate ..........................................................................................75 
 
2-3.  Entity Table  ..............................................................................................................................97 
 
2-4.  Rule Table..................................................................................................................................99 
 
2-5.  Baseline plasma concentration of coagulation factors ..............................................................102 
 
3-1.  Entity Table ...............................................................................................................................106 
 
3-2.  Rule Table .................................................................................................................................108 
 
3-3.  Baseline plasma concentration of coagulation factors ..............................................................109 
 
4-1.  DIC Results................................................................................................................................59 
 
 
vi 
 
 
 
 
LIST OF FIGURES  
 
 
Figure  ...............................................................................................................................................Page 
 
1.  Wound healing schema  ................................................................................................................19 
 
2.  Coagulation cascade and inhibitors  .............................................................................................23 
 
3.  Fibrinolysis cascade and inhibitors ...............................................................................................26 
 
4.  Computational modeling flow diagram ........................................................................................32 
 
1-1.  Model Schema ...........................................................................................................................41 
 
1-2.  Dependence of the pathogen growth rate on tissue oxygenation ..............................................44 
 
1-3.  Healing behavior of a small, ‘‘clean’’ wound ...........................................................................49 
 
1-4.  Nonhealing wound of large initial size and no initial pathogens ..............................................50 
 
1-5.  Transients for pathogen and damage with various O2 values ...................................................51 
 
1-6.  Long-term wound behavior for various choices of tissue oxygenation O2 and 
fibroblast mortality.............................................................................................................................52 
 
1-7.  Comparison of damage vs. time for different fibroblast recruitment rates ...............................53 
 
2-1.  Coagulation Cascade and Inhibitors ..........................................................................................65 
 
2-2.  Fibrinolytic Cascade and Inhibitors ...........................................................................................66 
 
2-3.  Spatial Grid  ...............................................................................................................................68 
 
2-4.  Computational Algorithm ..........................................................................................................70 
 
2-5.  Total thrombin generation with and without inhibitors  ............................................................76 
 
2-6.  Total thrombin generation profile with 130pM TF-VIIa with AT & TFPI ...............................79 
 
2-7.  Effect of aTAFI on the activation of plasminogen  ...................................................................80 
 
2-8.  Plasmin-Antiplasmin binding kinetics.......................................................................................81 
 
vii 
 
2-9.  Effect of PAI on the rate of plasminogen activation by tPA .....................................................82 
 
2-10.  Thrombomodulin concentration dependence of initial rates of TAFI activation  ...................82 
 
2-11.  Clot as a function of time when measuring the PT and aPTT of normal plasma ....................85 
 
2-12.  aPTT times under pathophysiologic conditions ......................................................................87 
 
2-13.  Effects of pharmacologic agents on coagulation assays ..........................................................88 
 
3-1.  Coagulation Cascade .................................................................................................................104 
 
3-2.  Thrombin generation as a function of TF-VIIa concentration in the presence of TFPI 
and AT. ..............................................................................................................................................114 
 
3-3.  Thrombin generation as a function of TM concentration in the presence of TFPI and 
Protein C ............................................................................................................................................115 
 
3-4.  Thrombin generation as a function of TM concentration in the presence of AT and 
Protein C. ...........................................................................................................................................115 
 
3-5.  Thrombin generation as a function of TM concentration in the presence of TFPI, 
AT, and Protein C ..............................................................................................................................116 
 
 
 
 
viii 
 
 
LIST OF ABBREVIATIONS 
 
a1-PI a1-protease inhibitor 
ABM agent based modeling 
ABMS agent based modeling and simulation 
AP anti-plasmin 
aPC activated protein C 
aTAFI activated thrombin activatable fibrinolysis inhibitor 
AT-H antithrombin III-heparin 
bFGF basic fibroblast growth factor  
CA cellular automata 
CAD coronary artery disease 
CAM  cell adhesion molecule    
cAMP cyclic adenosine monophosphate 
CF coagulation/fibrinolytic 
CVA cerebrovascular accident 
DIC disseminated intravascular coagulation 
DVT deep venous thrombosis 
ECM extracellular matrix 
Fg fibrinogen 
FGF fibroblast growth factor 
Fm fibrin monomer  
FSP fibrin split products 
GPU graphics processing unit 
H heparin  
HMWK high molecular weight kininogen  
HUS hemolytic uremic syndrome  
ICAM intercellular adhesion molecule 
IGF-1 insulin-like growth factor-1 
IL-1 interleukin 1 
IL-6 interleukin 6 
IL-8 interleukin 8 
ITP idiopathic thrombocytopenic purpura 
K kallikrein 
Ka kaolin  
KGF keratinocyte growth factor 
MMP-8 matrix metalloproteinase-8 
ODE  ordinary differential equation  
PAI plasminogen activation inhibitor 
ix 
 
 
PDGF platelet derived growth factor 
PG plasminogen 
PK prekallikrein 
Plt platelet 
Pn plasmin 
TAFI thrombin activatable fibrinolysis inhibitor 
TF tissue factor 
TFPI tissue factor pathway  inhibitor 
TGF-a transforming growth factor alpha 
TGF-b transforming growth factor beta 
TIC trauma induced coagulopathy 
TIMP tissue inhibitor of metalloproteinase 
TNF-a tumor necrosis factor alpha 
tPA tissue plasminogen activator 
TTP thrombotic thrombocytopenic purpura 
VCAM vascular cell adhesion molecule 
VEGF vascular endothelial growth factor  
   
 
x 
 
 
 
 
 
Abstract 
 
 
A COMPUTATIONAL BIOLOGY APPROACH TO  
THE ANALYSIS OF COMPLEX PHYSIOLOGY 
 
By Nathan Menke, M.D. 
 
An abstract submitted in partial fulfillment of the requirements for the degree  
of Doctor of Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2010.  
 
Major Director: Robert F. Diegelmann, Ph.D.  
Professor  
Department of Biochemistry and Molecular Biology 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
 
The birth of complexity research derives from the logical progression of advancement in 
the scientific field afforded by reductionist theory.  We present in silico models of two 
complex physiological processes, wound healing and coagulation/fibrinolysis based on 
two common tools in the study of complex physiology: ordinary differential equations 
(ODE) and Agent Based Modeling (ABM).  The strengths of these two approaches are 
well-suited in the analysis of clinical paradigms such as wound healing and coagulation.  
 
The complex interactions that characterize acute wound healing have stymied the 
development of effective therapeutic modalities. The use of computational models holds 
the promise to improve our basic approach to understanding the process.  We have 
modified an existing ordinary differential equation model by 1) evolving from a systemic 
model to a local model, 2) the incorporation of fibroblast activity, and3) including  the 
effects of tissue oxygenation. Possible therapeutic targets, such as fibroblast death rate 
and rate of fibroblast recruitment have been identified by computational analysis. This 
model is a step toward constructing an integrative systems biology model of human 
wound healing. 
 
The coagulation and fibrinolytic systems are complex, inter-connected biological systems 
with major physiological roles. We present an Agent Based Modeling and Simulation 
(ABMS) approach to these complex interactions. This ABMS method successfully 
reproduces the initiation, propagation, and termination of blood clot formation and its 
lysis in vitro due to the activation of either the intrinsic or extrinsic pathways. 
Furthermore, the ABMS was able to simulate the pharmacological effects of two 
xii 
 
 
clinically used anticoagulants, warfarin and heparin, as well as the physiological effects 
of enzyme deficiency/dysfunction, i.e., hemophilia and antithrombin III-heparin binding 
impairment, on the coagulation system.  The results of the model compare favorably with 
in vitro experimental data under both physiologic and pathophysiologic conditions. 
 
Our computational systems biology approach integrates reductionist experimental data 
into a cohesive model that allows rapid evaluation of the effects of multiple variables.  
Our ODE and AMBS models offer the ability to generate non-linear responses based on 
known relationships among variables and in silico modeling of mechanistic biological 
rules on computer software, respectively.  Simulations of normal and disease states as 
well as effects of therapeutic intervention demonstrate the potential uses of computer 
simulation.  Specifically, models may be applied to hypothesis generation and biological 
advances, discovery of new diagnostic and therapeutic options, platforms to test novel 
therapies, and opportunities to predict adverse events during drug development.  The 
ultimate aim of such models is creation of bedside simulators that allow personalized, 
individual medicine; however, a myriad of opportunities for scientific advancement are 
opened through in silico experimentation. 
 
Introduction 
Complexity Theory 
Classic scientific approach suggests that the universe may be understood through the study of its 
individual components, i.e. reductionism[1,2].  Through deconstruction of complex problems 
into their integral parts, the reductionist approach successfully predicts those outcomes perfectly 
explained through simple mechanistic behaviors.  This approach predefines the system as one 
composed of simple relationships between individual components, unaffected by the properties 
of the system itself; single causes result in single effects with small perturbations of the system 
as a whole. Particle physics and molecular biology are examples of fields that have made 
enormous gains through reductionist analysis.  In contrast, complex systems resist 
characterization in this manner.  
 
A system is a delineated part of the universe which is distinguished from the rest by a real or 
imagined boundary.  Systems may be characterized as open/closed and simple/complex.  Closed 
systems are maintained by internal forces and are not influenced by external forces.  Open 
systems, which are commonly found in biology, are in permanent interaction with their 
environment.  Therefore, in order to understand an open system you must describe the system, its 
environment, and the interactions between them.  Simple systems have single cause and effect, 
small change in cause results in small change in effect, thereby predictable.  Complex systems 
have circular causality, feedback loops, logical paradoxes and/or strange loops; small changes in 
cause have the potential to cause large effects, thereby displaying emergence phenomena and 
making them unpredictable[3].  In order to account for these multifactorial characteristics, the 
system approach attempts to combine both the reductionist and holistic approaches.  Complex 
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systems analysis endeavors to explain how simple entities without any central controller and 
limited communication can combine to form complicated and sophisticated systems.  By 
definition, complex systems exhibit emergent and self-organized behavior.  Adaptive, non-linear 
behavior may arise from seemingly small changes in initial conditions.  Unlike systems defined 
by linear relationships, initial conditions cannot predict the magnitude or direction of the 
outcome.  Thus, newer methods such as chaos theory, evolutional economics and network theory 
have evolved to explain complex systems such as weather/climate, societal behavior, and disease 
states of living organisms[4]. 
 
Analysis of complex systems requires an all-inclusive approach that acknowledges its 
heterogeneous components and processes.  Temporal and spatial variability are integrated as 
multiple cause/effect mechanisms may occur simultaneously.  The following critical properties 
are addressed first and foremost: 1) self-organization, i.e. no overriding controller, 2) non-linear 
relationships, and 3) emergence.  This analysis is further complicated by potential emergence of 
component parts.  A complex system may, in and of itself, be formed from a series of complex 
systems.  For example, individual organs (heart, brain, liver, etc…) are complex systems that 
contribute to the behavior of the organism as a whole.  In fact, each individual cell is also a 
complex system. 
 
The collective action of a complex system integrates the internal and external environment in a 
unique manner delineated through the properties within the system.  Interactions such as 
feedback loops, feedforward loops, circular causality, and self-organization result in emergence, 
whereby simple components produce complex behavior[5].  Through circular causality, the 
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sequence of cause and effects lead back to the initiating event in a manner that confirms or 
changes the initial circumstance (AB CA).  Feedback implies a loop whereby the product 
returns and affects the input.  Negative feedback reduces the deviation from a goal state 
(stabilization effects).  Positive feedback increases the deviation from an initial state 
(destabilizing).  Prediction of this behavior does not follow from the reductionist model of 
characterization of the individual components.  Dissection of these systems into its components 
mislays the complex behavior under investigation.   As a result, reductionist theory is unable to 
predict the behaviors of a system with emergent properties.  A hurricane results from a series of 
conditions involving pressure, condensation, and temperature gradients.  A living organism 
produces complex physiology/behavior from the local actions of cells. 
 
Unique properties emerge as a result of heterogeneous components interacting in a non-linear 
manner.  Nonlinear systems may show sensitivity to initial conditions where a small change in a 
variable may cause a large effect in the outcome of the system.  Conversely, vastly different 
initial conditions may generate non-unique solutions.  The systems show both time and state 
dependence in that they depend on not only the current state of the system, but also historical 
events.  The most important property of such systems is that they display emergent behaviors 
that cannot be predicted from analysis of the individual components.  In biological systems, 
emergent behaviors often result in highly ordered and stable systems.  Complexity science 
suggests that life is in accordance with the laws of physics, but physics first principles alone 
cannot predict life[6].  A more complete understanding of a system requires holism.  The holistic 
approach focuses on organizational principles where the emergent properties of a system arise 
from the interactions of its parts.   
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 In short, a complex nonlinear system may be viewed as a system consisting of an extremely large 
and variable number of components. These components are capable of displaying significant 
temporal and spatial variability but, at the same time, can retain a high degree of interdependence 
between each other.  What we learn from this is that topology and dynamics interact to produce 
system behaviors.  Thus, it is the combination of the dynamics of the various components 
themselves and the relationship or connections (nature and degree) between the components, 
which emerge as being of utmost importance.  A complex system renders distinction between 
cause and effect relatively meaningless as the dynamic relationship among components results in 
effects modifying causes to create new, independent outcomes.   
 
By definition, a complex system is one that satisfies certain critical properties. First, it is 
composed of many parts that are coupled in a nonlinear fashion with no overlying controller that 
determines the behavior of the system (the system must be self-organizing).  Second, the system 
must show emergence. That is, the whole system must contain properties that are unpredictable 
from the parts/component pieces of the network or system. Typically, in such systems, as the 
number of components and their relationships increase, the complexity also increases.  As a 
result of the spatio-temporal relationships of the system, the system may exhibit a variety of 
dynamical behaviors from stable flows to seemingly random oscillations.  Complex systems may 
demonstrate many other dynamical behaviors. Possible behaviors include sensitivity to initial 
conditions where a small change in a variable may oftentimes cause a large effect in the 
dynamical outcome of the system (butterfly effect)[7].  Other properties include hysteresis, a 
property in which model parameter sets may generate non-unique solutions with the same initial 
4
parameter conditions, and bifurcation dynamics where radically different behaviors such as 
going from stable to unstable or stable to oscillatory may occur over very small parametric 
ranges[8,9].  Spatial and temporal patterns can exhibit properties of self-similarity (fractality) in 
which changes in scale visualization of the pattern show no alteration in the basic structure of the 
pattern itself[10,11].  Systems can exhibit self-organization and coalescence, evolution and 
adaptation[12].
 
 Finally, system dynamics may contain n historical component in which the 
temporal dynamics of the system, at a particular time point, is partially or fully dependent upon 
the prior history (dynamical behaviors) of the system or its components.  
 
Reductionist approaches dissect systems in order to better understand its' nature.  However, one 
of the fundamental properties of synergistic complex systems is that subfractionation can and 
does cause a loss of information (structural, relational, temporal and hierarchical).  Subsequently, 
destruction of emergent properties that are not contained within the subfraction pieces occurs. 
Despite the fact that upper level hierarchical structures may contain a super emergent dynamics 
set, sub-levels may contain their own emergent dynamics that are not necessarily seen until the 
sub-level is separated from the whole system.  One must be clear that sublevel emergence is 
potentially artifactual due to the breaking of links to the whole system. These emergent 
properties are always present in the whole system but are invisible and cannot be appreciated 
from a reductionist approach.  Thus, we cannot dissect a complex system in the parts, study them 
and expect to fully understand the system.  Dissection of the overall system destroys the 
important ingredient of semantics-syntax, context dependence, and self-reference; properties that 
are vital in the production of emergent behaviors.  To summarize, complex systems are 
composed of  many components connected in a non-linear manner, must be self organizing, no 
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overlying controller, must show emergence, and contains properties that are unpredictable from 
the individual components of the system.  As a result of these properties, a complex system 
cannot be dissected and studied as individual components. 
 
Examples of complex systems are found throughout the natural world[13].  As described above, 
climate, human behavior, and disease processes all exhibit complex function[14,15].   These 
examples may be further subdivided or expanded into additional complex systems.  Climates are 
complex systems that affect the emergent behavior of ecosystems.  Within ecosystems, complex 
behavior is exerted through herd mentality, the eruption of a volcano, the gathering patterns of 
ants and bees[16].   
 
Humans behave in a complex manner, from flight patterns to societal organization of economies 
and politics to the functioning of the internet[17,18,19].  The integration of numerous individual 
and societal relationships in the United States results in the election of a president[3].  
Combinations of supply and demand produce economic outcomes that differ from predicted 
linear relationships. 
 
Medical and biological processes are a field of acute interest for complex systems analysis[20].  
Individual organs and their inherent functions produce complex behavior, as does their 
interaction as a whole.  Heart rate variability, immune system response, and phenotypic variation 
result from disparate inputs[21,22].  In this manner, biologic complexity defies reductionist 
patterns of recognition[23].  As most disease states result from dysfunction of complex systems, 
newer methods of analysis offer an innovated, personalized approach currently lacking in the 
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biomedical sciences.  Herein, emergent properties of pathophysiological states of wound healing 
and coagulation/fibrinolysis are characterized.  A series of in silico experiments using ordinary 
differential equations (ODEs) and agent based modeling (ABM) demonstrates the potential 
application of a systems biology approach in these disease states. 
 
Biologic Complexity 
Wound Healing - The normal response to tissue injury is a timely and orderly reparative process 
that results in sustained restoration of anatomic and functional integrity[24].  In contrast, in 
chronic dermal ulcers the healing process is prolonged, incomplete, and proceeds in an 
uncoordinated manner resulting in poor anatomical and functional outcome. On the opposite end 
of the spectrum are the numerous clinical problems associated with excessive healing and 
fibrosis. Clinically, wounds can be categorized as acute or chronic based on the timeliness of 
healing[25].  
 
Wound repair is a complex process involving a highly regulated cascade of events requiring 
interactions among many cell types, soluble factors, and matrix components[26]. There are four 
distinct phases of acute wound healing consisting of hemostasis, inflammation, proliferation, and 
remodeling.  Following injury, exposure of platelets to the extracellular matrix (ECM) induces 
them to adhere and aggregate, thus, releasing the contents of their secretory granules. This 
hemostasis response occurs immediately following tissue disruption and is needed to control 
bleeding and seal the site of injury. The wide variety of platelet factors liberated by 
degranulation include those which facilitate hemostasis and also act as chemoattractants [platelet 
7
derived growth factor (PDGF) and transforming growth factor beta (TGF-B)] for cells involved 
in the next stage of repair, the inflammatory phase. 
 
The process of hemostasis begins immediately upon injury. The immediate goal is to stabilize 
the wound and thereby prevent exsanguination. Exposed blood vessels vasoconstrict and 
platelets that are exposed to collagen are activated and begin the process of aggregation at the 
wound site. These activated platelets release growth factors, cyclic adenosine monophosphate 
(cAMP), and adhesive glycoproteins, which in turn activate receptors that cause platelets to 
become sticky and aggregate. The glycoproteins released from activated platelet alpha granules, 
include fibrinogen, fibronectin, thrombospondin, and von Willebrand factor. The next step in 
hemostasis involves the coagulation cascade as coagulation factors from the blood combine with 
coagulation factors released by platelets. The result is a fibrin clot that not only prevents further 
blood loss, but also serves as a provisional wound healing matrix[27]. Platelets become 
entrapped in the fibrin clot providing further bulk as well as a membrane on which inactive 
clotting enzymes are bound and activated further promoting the clotting cascade. 
 
Growth factors released by the platelet alpha granules provide the impetus for the next stage in 
wound healing.  Neutrophils and monocytes are recruited and activated by PDGF and TGF-B. 
Endothelial cells are activated by vascular endothelial growth factor (VEGF), transforming 
growth factor alpha (TGF-a), and basic fibroblast growth factor (bFGF).  Fibroblasts are 
activated by PDGF to begin migration to the wound site and produce collagen and 
glycosaminoglycans, which facilitates cellular migration and interactions with the cell matrix-
supporting framework. In addition to factors released from platelets, breakdown fragments from 
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complement, such as C5a and f-Met-Leu-Phe, a bacterial waste product, also signal and recruit 
neutrophils to the wound site. In sum, hemostasis initiates the wound healing response through  
platelet activation at the site of the injury, and the interactions of soluble mediators and growth 
factors with the ECM to provide the provisional wound healing matrix that sets the stage for 
subsequent events. 
 
The inflammatory phase begins as early as 2 h after injury.  Activated neutrophils leave the 
circulation to begin the debridement of devitalized tissue and phagocytosis of any infectious 
agents or foreign bodies.  Neutrophils also secrete cytokines and other specific chemical 
„„signals‟‟ needed to attract specialized cells that are important in repairing the injured 
tissue. In addition, neutrophils release a battery of proteolytic enzymes, such as elastase and 
matrix metalloproteinase-8 (MMP-8), to assist in their movement through the tissue and remove  
damaged ECM[28,29,30].  Mast cell granules are filled with enzymes, such as chymase and 
tryptase, histamine, and other active amines; when released these enzymes cause the classic signs 
of inflammation: rubor (redness), calor (heat), tumor (swelling), and dolor (pain). The crucial 
inflammatory cells during the inflammatory phase are neutrophils and activated monocytes 
(macrophages). Neutrophils and macrophages are responsible for bound wound bed preparation 
and the initial milieu of the healing wound. In order to expedite healing, cellular debris and 
bacteria are cleared. The inflammatory cells also release cytokines [including interleukins 1 (IL-
1), IL-6, IL-8, and tumor necrosis factor alpha (TNF-a)] and growth factors [PDGF, TGF-B, 
TGF-a, insulin-like growth factor-1(IGF-1), and FGF] that not only serve to continue the 
inflammatory phase but also initiate the proliferative phase by recruiting fibroblasts and 
epithelial cells. 
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 In the first 24 h, neutrophils are the predominant inflammatory cell type.  The neutrophils are 
recruited and activated by the soluble mediators released by platelets and the coagulation cascade 
during the hemostatic phase. The initial goal of the neutrophils is to prepare the wound bed by 
killing bacteria and removing devitalized tissue. Not only does this begin the process of 
wound healing but also helps fight infection. Neutrophils are chemoattracted to the wound site 
by the initial inflammatory cytokines released at the time of injury and subsequent hemostasis 
process. Normally, the weak adherence of leukocytes results  in a rolling type motion along the 
surface of the endothelial cells. The slower velocity allows more time for binding between the 
adhesion molecules [selectins, cell adhesion molecules (CAMs), and cadherins] and receptors 
(integrins) of circulating leukocytes and vascular endothelial cells. Once activated, leukocytes 
firmly adhere to epithelial cells as a result of the binding between integrin receptors and ligands, 
such as vascular CAM (VCAM) and intercellular adhesion molecule (ICAM), which are 
expressed on activated endothelial cells. The activated leukocytes are induced to migrate 
between the endothelial cells and move into the injured tissue using their integrin receptors to 
bind to ECM components. At that point, inflammatory cells secrete elastase and collagenase in 
order to migrate through the basement membrane of the endothelial cell and into the ECM. Once 
the neutrophils have entered the wound, they begin to phagocytose bacteria and subsequently 
produce oxygen free radical to kill the entrapped bacteria. In addition, they degrade damaged 
components of the ECM by releasing large amounts of proteases (neutrophil elastase and 
neutrophil collagenase). Neutrophils also produce and release inflammatory mediators, such as 
TNF-a and IL-1, which further recruit and activate more neutrophils as well as fibroblasts and 
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epithelial cells. After 2–3 days, neutrophils are no longer the dominant cell type as they are 
depleted by apoptosis allowing tissue monocytes to predominate.   
 
After the first 24 h, activated monocytes (macrophages) are the most numerous inflammatory 
cell types present in the wound bed.  Macrophages are not only active in healing the wound but 
also in the regulation and progression of the healing process. Macrophages are mandatory 
components of the normal healing process[31]. Circulating monocytes are attracted to the wound 
site and extravasate in the same manner as described for neutrophils.  Once the monocyte has 
entered the wound site, they are activated into tissue macrophages by chemokines, cytokines, 
growth factors, and soluble fragments of ECM components produced by proteolytic degradation 
of collagen and fibronectin. Macrophages play a similar role as neutrophils in the healing 
process. They are responsible for killing bacteria and wound debridement through the actions of 
secreted MMPs and elastase. In addition to the functions shared with neutrophils, the 
macrophages also play a crucial role in modulating the inflammatory response by regulating the 
proteolytic destruction of wound tissue and initiating the transition from the inflammatory phase 
to the proliferative phase.  Macrophages downregulate tissue destruction by secretion of 
inhibitors of the proteases. They also release a wide variety of growth factors and cytokines 
including PDGF, TGF-B, TGF-a, FGF, IGF-1, TNF-a, IL-1, and IL-6 that serve to recruit and 
activate fibroblasts and promote angiogenesis. The addition of fibroblasts that synthesize, 
deposit, and organize the provisional ECM, combined with the ability to decrease proteolytic 
destruction leads to the initiation of the proliferative phase. As the number of macrophages 
decrease and the number of fibroblasts increase the wound begins to enter the proliferative phase 
and exit the inflammatory phase. 
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 During the „„proliferation‟‟ phase, keratinocytes proliferate, migrate, and differentiate, thus, 
restoring surface integrity. Endothelial cells from damaged blood vessels begin to send out new 
capillary buds, while fibroblasts from nearby connective tissue enter the wound site and deposit 
ECM[32].  In the normal dermis, fibroblasts are quiescent and have a low concentration, but in 
granulation tissue and the provisional matrix of the wound they are active and exist in high 
concentrations.  Fibroblasts are recruited to the wound site by the soluble products of activated 
platelets and macrophages.  The migration of fibroblasts is far more complicated than that of 
neutrophils and macrophages as they have to change their morphology and clear a path for their 
movement from the ECM to the wound site.  
 
Fibroblasts begin their migration by first binding to matrix components (fibronectin, vitronectin, 
and fibrin) via their integrin receptors. The receptors bind to specific amino acid sequences (R-
G-D or arginine–glycine–aspartic acid) or binding sites on the matrix components. The 
fibroblasts move in a step-wise pattern by extending a cytoplasmic projection from the unbound 
side of its membrane to find the next binding site. Once a new site is successfully bound, the 
original site is then released (by local protease activity), and the cell pulls itself forward using its 
cytoskeleton network of actin fibers.   
 
The concentration gradient provided by chemotactic growth factors, cytokines, and chemokines 
in conjunction with the alignment of the fibrils in the ECM and provisional matrix determine the 
direction of fibroblast migration.  The fibroblast moves along the fibrils as opposed to across 
them. The proteolytic enzymes used to facilitate their forward motion include collagenase 
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(MMP-1), gelatinases (MMP-2 and MMP-9) that degrade gelatin substrates, and stromelysin 
(MMP-3) that has multiple protein substrates in the ECM.   
 
Collagen is the major ECM component providing strength, integrity, and structure to normal 
tissues. It is also required to repair defects created by injuries, thereby restoring tissue structure 
and function[32,33].  During repair, collagen is initially laid down in irregular bundles 
possessing modest mechanical strength, but as the wound matures, the collagen is cross-linked 
and then the scar undergoes remodeling indicating the „„maturation‟‟ phase of healing. The 
collagen is then organized into a dense structure with increasing tensile strength as the matrix 
begins the process of contraction.  However, the regained tensile strength will never reach 
normal; the maximum a wound can ever achieve is approximately 80% of normal tensile 
strength[32,33]. Other components of the ECM that exhibit significant structural and functional 
roles include fibronectin, laminin, proteoglycans, and glycosaminoglycans[34]. Fibronectin and 
laminin contain important binding sites for cells, collagen, as well as glycosaminoglycans[35].   
 
Wounds with significant tissue loss heal by the mechanism of contraction, a process whereby the 
edges of a wound are drawn toward the center, due to forces generated within the wound. 
Contraction facilitates spontaneous wound closure by reducing the volume required to be filled 
by granulation tissue as well as the area required to be re-epithelized[33,36].   
 
In order to protect the underlying wound it is necessary to create an epithelial barrier. 
Epithelization is a complex process that involves epithelial cell detachment phenotypic 
alterations, migration, proliferation, and then differentiation[37].  An undamaged mature 
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epidermis consists of five layers of differentiated epithelial cells ranging from the cuboidal basal 
keratinocytes nearest to the dermis up to the flattened, hexagonal, and tough keratinocytes in the 
uppermost layer. Only one layer is capable of replication (the basal epithelial cells). These basal 
cells are normally attached to their neighboring cells by intercellular connectors called 
desmosomes and to the basement membrane by hemidesmosomes. In order to begin replicating 
basal cells must become activated by growth factors such as EGF, keratinocyte growth factor 
(KGF), and TGF-a. The growth factors bind to receptors on the epithelial cells and stimulate 
migration and proliferation. In addition to the activation of  basal cells, growth factors trigger the 
desmosomes and hemidesmosomes to dissolve.  Subsequently, cells may detach in preparation 
for migration. Integrin receptors are then expressed and the normally cuboidal basal epithelial 
cells flatten in shape and begin to migrate as a monolayer over the newly deposited granulation 
tissue, following along collagen fibers.  The monolayer is provided with new cells from the 
proliferating basal cells near the wound margin (cells that are actively migrating are incapable of 
proliferation). In order for the epithelial cells to penetrate the newly formed scab, necrotic tissue, 
or escar, the leading edge of the monolayer produces and secretes proteolytic enzymes (MMPs). 
The migration ceases after the epithelial cells contact each other.  Once this contact has been 
made, the entire epithelial monolayer forms a confluent sheet and enters a proliferative mode and 
the stratified layers of the epidermis are reestablished and begin to mature to restore barrier 
function. The intercellular desmosomes and the hemidesmosome attachments to the newly 
formed basement membrane are also reestablished. TGF-B is one growth factor that can speed 
up the maturation (differentiation and keratinization) of the epidermal layers. Clinically, 
epithelialization is the hallmark of healing, but it is not the final event, as the granulation tissue 
must be remodeled to form the permanent scar. 
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 During late phases of wound healing, scar remodeling involves a variety of matrix degrading 
enzymes including MMPs, serine proteinases, cathepsins, and glycosidases[36,38]. The goal of 
the remodeling phase is the conversion of the preliminary wound matrix to the production of a 
final scar that maximizes wound tensile strength.  Fibroblasts are the cells responsible for 
remodeling.  An equilibrium between collagen formation and degradation results in a constant 
amount of collagen. There are several different classes of proteolytic enzymes in the wound bed 
that are responsible for the degradation of collagen: MMPs, serine proteinases, cathepsins, and 
glycosidases[36,38]. Specific MMP proteases required for remodeling include collagenases 
(which degrade intact fibrillar collagen molecules), the gelatinases (which degrade damaged 
fibrillar collagen molecules), and the stromelysins (which very effectively degrade 
proteoglycans). The most important serine protease is neutrophil elastase, which can degrade 
almost all types of protein molecules. In order to balance the destructive capabilities of the 
matrix degrading enzymes, inhibitors are also needed. The specific inhibitors of the MMPs are 
the tissue inhibitors of metalloproteinases (TIMPs) and specific inhibitors of serine protease are 
a1-protease inhibitor (a1-PI) and a2-macroglobulin. The process of remodeling is dependent on 
the relative activities of the proteases and their inhibitors.  
 
Tightly controlled regulatory systems maintain a delicate balance between these complex 
synthetic and degradative processes; normal tissue repair ultimately results from a fine-tuning of 
this equilibrium. There is now a growing recognition that abnormal wound healing often results 
from a disruption of degradative/synthesis equilibrium[29,30,39,40,41]. When the balance tips in 
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favor of matrix degradation, the end result may be a chronic ulcer, where as reduced degradation 
and/or increased matrix synthesis results in fibrosis.  
 
Research scientists and clinicians have focused historically on the effects of cytokines and 
growth factors on individual cells in vitro, out of context of both the injury and the organism[42].  
The relationships among the various cell types and the dynamics of the wound healing process 
has remained uncharacterized.  As a result, therapies to improve wound healing have either failed 
or shown minimal improvements in outcomes.  One possible reason for such failures is that the 
complex, multi-scale, multi-temporal, hierarchical nature of wounds has thus far been 
underappreciated.  In order to account for these relationships, an overarching systems biological 
approach would allow one to draw upon the nuanced methodologies of complexity 
theory[43,44].  Fueled by the ongoing identification of numerous inflammatory and immune 
mediators produced in the normal response to acute soft tissue injury, ample evidence of this 
oversimplification can be found in the failure of single mediator-targeted therapies.  Many 
features of the wound healing process are consistent with complexity theory: 1) Multiple cell 
types  interact using paracrine and autocrine signaling (signals may be amplified/dampened 
based on the state and history of the individual cell in a non-linear manner) 2) There is no 
overlying control mechanism 3) The process of wound healing progresses through hemostasis, 
inflammation, proliferation and remodeling 4) A mature scar is produced that restores anatomical 
and function to the wound.  
 
These concepts apply to the problem of understanding and modeling the dynamics of a healing 
wound detailed below. The wound healing system is composed of multiple levels of 
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organizational scale including: multiple cell types (fibroblasts, neutrophils, macrophages, etc…), 
intercellular messengers (cytokines, chemokines, hormones, growth factors, etc…), synthetic 
products (collagen, proteoglycans, etc…), and enzymes (MMPs and TIMPs).  The different cell 
types produce and respond to the same cytokines in an autocrine and paracrine manner (multiple 
pathways of interaction).  As a result, a signal may be quickly amplified in the system or 
dampened.  The feedback loops that control the release and effects of the cell signals produce 
nonlinear behavior.  The behavior of the cells is determined not only by the current state of the 
wound, but also the individual receptors that have been activated at earlier time points (state-
dependent and history-dependant behaviors).  The normal process of wound healing contains 
many separate but interacting events and host responses including microcirculatory oxygen 
transport, immune and inflammatory responses, metabolic changes, and the neuroendocrine 
system modulation.  An unknown degree of these and secondary responses will occur due to 
complex changes in genome expression.  Instead of viewing each of these responses as separate 
and independent mechanisms involved in the development of a healed wound it must be argued 
that events leading to healing should be viewed through the complexity theoretic lens and that 
wound healing is most effectively studied as a complex nonlinear system.  Additionally, the 
intracellular signaling pathways also consist of a complex system in itself (sub-system 
hierarchies).  Within each cell, there are multiple pathways that when activated by a receptor, 
amplify a signal.  Many times there are pathways that directly oppose each other that lead to 
measured responses (multi-scale interaction).  Cross talk and divergent pathways lead to many 
complex relationships among the various signaling pathways.  Therefore, a wound must be 
considered a complex system composed of components that are themselves complex systems 
(modular hierarchies of complex systems). 
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  Based on the previous discussion, it is clear that the study of the dynamics of wound healing 
cannot be approached solely through traditional reductionist methodologies.  We have 
established that the experimental understanding currently demonstrates that wound healing is a 
highly complex process that involves multiple cell types all of which are interacting in a 
nonlinear fashion.  These interactions take place over different time scales, across different 
organismal hierarchies, and generate relationships through which unpredictable emergent 
properties can occur[45,46].  For example, there are many feedback loops and redundancies in 
the wound healing network (Figure 1) that make wound healing difficult to study.  Feedback 
loops give rise to the potential for oscillatory behavior, chaotic dynamics, and other nonlinear 
phenomena. Topological structure of the network can give rise to unpredicted properties that are 
defined, not by dynamical relations, but rather by spatio-structural ones[47,48].  Thus, it is not 
sufficient to understand healing dynamics in terms of classical chemical reaction mechanisms; 
rather, we must examine the integration of topological (spatio-structural and hierarchical) and 
temporal (multi-scale) perspectives in order to truly understand the underlying mechanisms of 
wound healing. 
 
The previous description of complex nonlinear systems, as applied to wound healing, is highly 
attractive in attempting to explain our failure in creating successful mono-target therapies.  New 
understandings tell us that the cells involved in wound healing and the cytokines and growth 
factors used to transmit signals could be better categorized as highly complex, layered, modular 
networks with stochastic dynamics at risk for dysfunction. The extent to which acute and chronic 
soft tissue wounds can be modeled in terms of complex nonlinear systems, based on the 
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 Figure 1: Wound Healing Schema.  The schema demonstrates the multiple feedback loops and 
interactions among the components of the wound healing process. 
 
preceding discussions and assumptions, is not at all clear.  Examining the wound healing process 
as a complex system may allow for discovery and for analysis of possible important emergent 
properties of the system.  These emergent properties, which again, can only be appreciated from 
the whole of the interactions within the system, are what hold the potential promise of 
breakthroughs in treatments and diagnostics.         
 
Understanding that wound healing is most realistically represented through complexity theoretic 
viewpoints now allows the traditional reductionist philosophy to be potentially complemented by 
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the increasingly powerful new concepts of complexity theory.  Effective studies of complex 
systems must be made by analysis of the parts followed by a sophisticated reconstitution or 
synthesis in order to model as much of the system as is known at the given time.  The resulting 
model must allow for almost an infinite number of input variables and provide a means to 
interact with it.  In essence, the resulting model is itself desired to exhibit its own emergent 
properties allowing science to catch the necessary glimpses that provide for the creation of new 
hypotheses.  Manipulation of such a model will provide direction as to the subsequent approach 
needed to take the next generation of steps in discovery.  
 
An important concept while discussing normal wound healing is the concept of feedback and 
feedforward loops. In order for wound healing to progress in a coordinated manner, each stage in 
the healing process must not only self-perpetuate but also initiate the next stage. Furthermore, 
each progressive stage must have the ability to turn off the previous stage once it has reached the 
critical point at which it is no longer dependant on the previous stage for positive feedback to 
continue. The interlocking feedback/feedforward loops allow for an orderly progression of 
wound healing and prevents any one stage from inhibiting and/or preventing progress into the 
next stage. The mechanism by which the different phases inhibit and promote each other is 
through the expression of soluble mediators such as growth factors and cytokines. Each cell type 
involved is capable of responding to and releasing a multitude of factors that allows the 
formation of feedback/forward loops to control cell concentrations as well as activity.  
 
In chronic wounds, failure of the normal wound healing process prevents normal wound closure. 
There are multiple etiologies for the formation of chronic wounds that include diabetic ulcers, 
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venous stasis ulcers, and pressure ulcers.  Although ischemia is an underlying cause, each of 
these wounds results from different pathological mechanisms; however all non-healing wounds 
have remarkably similar wound healing trajectories as well as similar inflammatory profiles. In 
the chronic wound, neutrophils are the predominant cell type with large amounts of proteases 
and inflammatory cytokines. Because of the excessive amount of inflammation, it is likely that 
these wounds have failed to progress from the predominantly inflammatory phase to a 
predominantly proliferative phase. The wound is not able to mature, and the disorganized ECM 
degrades liberating breakdown products, thus, causing further inflammation. As a result, the 
chronic pressure ulcer becomes enmeshed in an inflammatory phase that self-perpetuates without 
providing enough forward momentum to propel the process to the next stage of wound healing. 
The effect of chronic inflammation is further tissue destruction and worsening of the chronic 
wound thereby causing more inflammation and preventing any progress towards a healed wound.  
 
Coagulation & Fibrinolysis- The coagulation and fibrinolytic (CF) systems comprise a series of 
zymogen to enzyme conversions which ultimately terminate in the active proteolytic enzymes 
thrombin and plasmin, respectively[49].  These enzymes catalyze the deposition and removal of 
fibrin. When the system is functioning properly, blood is maintained in a fluid state yet rapidly 
clots to seal endothelial injuries.  A proper balance between the activities of the two cascades is 
required both to protect the organism from excessive blood loss upon injury and to maintain 
blood fluidity within the vascular system. Imbalance of the two cascades range from the full 
spectrum of bleeding disorders (e.g. hemophilias) to thrombotic events (e.g. heart attacks and  
strokes). 
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In the event of injury to the endothelium, the CF system balances the need for localized clot 
formation against the need to prevent system wide activation[50].  This finely tuned system is 
composed of an assortment of molecular and cellular “agents” (e.g. substrates, enzymes, 
cofactors, inhibitors, platelets, white blood cells and endothelial cells) which interact to generate 
a stable clot in order to rapidly obtain hemostasis.  The new cellular model of hemostasis 
proposes that the classical pathways of coagulation, i.e., the intrinsic and extrinsic pathways, 
mediate on specific cell surfaces in a tightly regulated manner. In this model, activation of factor 
VII (extrinsic, Figure 2) and factor XII (intrinsic, Figure 2) result in the formation of multi-
molecular complexes, the tenase and prothrombinase complexes, which eventually generate 
thrombin. Thrombin then cleaves fibrinogen to form fibrin monomers, which polymerize to form 
a three-dimensional clot[51].   
 
Clot formation is regulated in vivo primarily through the antithrombin III-heparin (AT-H), 
activated protein C (aPC), and tissue factor pathway  inhibitor (TFPI) pathways (Figure 
2)[52,53,54].  These regulating systems limit the excessive formation of cross-linked fibrin under 
hemostatic conditions thereby preventing thrombotic diseases. 
 
The blood coagulation system is always active and primed for explosive generation of thrombin.   
The positive feedback of the coagulation cascade in association with the negative feedback loops 
of the three inhibitory systems (AT-H, aPC, and TFPI) imparts threshold properties to the 
coagulation pathways[55,56,57].  As a result, there is a non-linear response to stimuli.  
Furthermore, the presence of multiple coagulation inhibitors that act at different locations in the 
cascade leads to a synergistic inhibition of explosive thrombin generation.  Thus, there must be a 
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 Figure 2: Coagulation Cascade and Inhibitors- Inhibitors denoted by circles.  The intrinsic 
pathway is initiated by Prekallikrein or XII.  The extrinsic pathway is initiated by TF.  The 
intrinsic and extrinsic pathway joins at the common pathway that begins after Factor X 
activation.  AT, TFPI, and aPC are the three inhibitory pathways.   
 
significant pro-coagulant stimulus to overcome the inhibitory systems of coagulation.  The 
threshold effect and non-linear response of the coagulation system prevents activation when it is 
not needed and localizes the response when it is needed.      
 
The specificity of interactions, both molecular and cellular, involved in these complex processes 
implies that systemic effects displayed by the CF system occurs through emergence of localized 
events.  The CF system may be viewed as a multi-component molecular machine,
 
in which 
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individual components are linked through multiple feedback and feedforward loops.  This 
introduces non-linear relationships among the components. A static diagram such as the 
classically portrayed coagulation pathway (Figure 2) cannot adequately describe this dynamic 
evolutionary network. Not surprisingly, the effects of several disease states on the imbalances in 
the CF system are difficult to characterize utilizing the classic coagulation pathway.  For 
example, the influence of diseases that favor coagulation (e.g. coronary artery disease (CAD), 
disseminated intravascular coagulation (DIC), cerebrovascular accidents (CVA), and deep 
venous thrombosis (DVT)), or those that impair coagulation (e.g. hemophilias, 
thrombocytopenias, and von Willebrand disease) remain poorly characterized in terms of the 
interactions of all components in the system over time. 
 
Coagulation is the first step in the repair of the damaged vessel[58].  Primary hemostasis is 
defined by the formation of the hemostatic plug composed of platelets at the site of injury.  
Secondary hemostasis is defined as the formation of fibrin strands by proteins in the blood 
plasma, called coagulation factors that respond in a complex cascade which strengthen the 
platelet plug.  Secondary hemostasis occurs simultaneously with primary hemostasis.  The 
coagulation cascade is a network of biochemical pathways that perform the critical function of 
preventing blood loss and repairing damage to the vasculature.  The overall network is divided 
into two major pathways: the intrinsic system and the extrinsic system. The intrinsic and 
extrinsic systems converge to form a final common pathway .  The common pathway leads to the 
formation of α-thrombin.  Thrombin serves to cleave fibrinogen to fibrin monomers.  The fibrin 
monomers then spontaneously polymerize to form a three-dimensional polymer = clot.   
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The coagulation cascade is tightly regulated to limit the excessive formation of cross-linked 
fibrin under hemostatic conditions and prevent spontaneous clot formation.  The three systems 
are the AT–heparin pathway, the tissue factor pathway inhibitor pathway , and the activated 
protein C pathway (aPC).   
 
Once the endothelial damage is repaired, the clot must be dissolved to allow wound healing to 
progress normally.  The fibrinolytic system operates to dissolve the pre-formed clot once the 
underlying damage has been repaired (Figure 3)[59,60].  Fibrinolysis is achieved primarily 
through the proteolytic action of plasmin on the fibrin polymers that reinforce and maintain the 
integrity of a thrombus.  Plasmin hydrolyzes the fibrin mesh at various places thereby making it 
soluble.  The dissolution of the fibrin clot produces circulating fragments that are cleared by 
other proteases or by the kidney and liver.  Similar to coagulation, the fibrinolytic system is 
composed of interlocking positive and negative feedback loops.  
 
Clot lysis is regulated in vivo primarily through the anti-plasmin (AP), plasminogen activation 
inhibitor (PAI), and thrombin activatible fibrinolysis inhibitor (TAFI) pathways (Figure 
3)[59,61,62,63,64,65,66].  Under normal conditions, these regulating systems delay the onset of 
clot fibrinolysis until coagulation is complete.  
 
The CF system has characteristics that make it difficult to study. The system is either at rest or 
activated, i.e. nonstationarity.  The system is not a homogenous chemical system (spatial 
heterogeneity) in that clotting is localized at the site of endothelial injury.  Lastly, the effects of 
blood flow lead to continuous changes in coagulation factor concentrations and mechanical 
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stresses on the clot.  The complexity of the coagulation system has lead to difficulty in creating 
therapeutic modalities.  New pharmaceutical agents that modulate hemostasis have been 
introduced into clinical practice such as recombinant factor VIIa and activated protein C.  The 
utility of these agents has been limited by the lack of measurement tools to characterize 
coagulopathy .  There is limited ability to determine: 1) indications 2) timing 3) dose of 
administration.  This has led to large scale, expensive but ultimately equivocal clinical trials. 
 
In addition to the inherent characteristics of the CF systems that make it difficult to study, the 
fact that the CF system is a complex system adds further difficulties.  The CF system is 
composed of a heterogenous collection of components including zymogens, enzymes, co-factors, 
inhibitors, membrane surfaces and multiple cell types (endothelial cells, platelets, and white 
blood cells).  The CF system has no overlying controller and is composed of a series of local 
Figure 3: Fibrinolytic Cascade and Inhibitors-  Inhibitors are denoted by circles.  The 
fibrinolytic pathway is initiated by tPA activation of Plasminogen.  Plasmin hydrolyzes fibrin.  
Plasmin and fibrin catalyze the conversion of Plasminogen to Plasmin 
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biochemical reaction.  The biochemical reactions that govern the system by their very nature are 
non-linear.  Lastly, threshold effects, localized clot formation, and time delayed fibrinolysis 
emerge from the simple reactions of the heterogenous components. 
 
One approach to approaching the study of the CF system is to integrate computational models 
with the experimental data.  The ideal computational model would allow the study of complex 
diseases that involve coagulation such as DIC, trauma induced coagulopathy (TIC), cardiac 
arrest, sepsis, DVT, MI, arterial thrombosis, genetic coagulopathy (hemophilia A/B, von 
Willibrands disease, AT deficiency, factor V leiden, etc...), acquired coagulopathy (thrombotic 
thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), idiopathic 
thrombocytopenic purpura (ITP), thrombocytopenia, etc...).  The model would find novel 
mediators effecting coagulation, discover new therapeutic targets and treatment strategies.  
Utilizing such as model would allow for testing over millions of iterations using the in silico 
model.  The outcomes associated with the model would include creation of bedside tools for real-
time outcome determinations and dosing adjustments, enhance the probability for success once 
the therapy is translated into the clinical setting, discover  new mediators effecting coagulation 
and interactions between systems including their proximal and distal effects, discover  new 
diagnostic and therapeutic targets that modulate the coagulation cascade to enhance outcomes, 
create predictive tools for real-time outcome determinations of a patient‟s clinical state, create 
real-time bedside tools to perform on-the-fly dosing adjustments for patients with simple or 
complex coagulopathies or thrombotic disorders, and develop new software and algorithms for 
simulation. 
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Computational Biology 
Due to the complex nature of biological systems, attempts to model them have concentrated on 
simple, idealized versions.  More recently, the traditional division of science into theory and 
experiment has been complemented by computer simulation.  A model is defined as a simplified 
representation of a real system.  Models are designed to: 1) describe phenomenon in such a 
manner as to be comprehensible 2) make predictions.  Models are used to explore general 
mechanisms underlying complicated phenomena through: 1) examining (im)plausibility of a 
proposed mechanism, 2) examining the effects of variations on simple models, and 3) acting as 
virtual experiments to gain intuitive understanding of complex phenomena[3,67]. 
 
Fields such as mechanical engineering have successfully used computer models in the design of 
tangible products such as automobiles and airplanes.  When using computers to model complex 
systems, they are used to model ideas.  Simulations may be the only means available for 
exploring complex systems when experiments are not feasible or they may be used to reduce the 
time and cost performing “real” experiments.  Such synthetic frameworks allow investigation of 
systemic behaviors in biologic systems that are difficult if not impossible to study in vivo. 
 
The idea that “All models are wrong, but some are useful" is critical for understanding the role of 
computer simulations in the examination of complex systems.  Models may lack universal 
application, yet may still lead to new insights, new ways of examining phenomena, improved 
models, and tools to build better models.  A crucial component in the utilization of models is 
understanding the limitation of the model, so that false conclusions are not derived from any 
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results.  The art of model building is the exclusion of irrelevant parts of the problem and correct 
interpretation of the results.   
 
Model building of complex systems poses unique challenges.  As discussed earlier, a system is 
defined as a collection of interacting elements that together produce, by virtue of their 
interactions, some system wide behavior.  In complex systems, the loss of emergent properties 
that define the system prohibits an understanding of the system by studying the individual parts.  
It is analogous to understanding the operation and construction of the space shuttle by reading its 
parts inventory.  Therefore, the system must be studied in a dynamic manner over time and 
characterizing not just the components but also their relationships.  For example, studying the 
characteristics of isolated structures of a cell in isolation inadequately characterize the behavior 
of the cell as a whole.  Models based on computational systems biology attempt to integrate 
experimental and computational research[68,69,70,71].  Ideally, computational systems biology 
will provide tools to bridge the gap between traditional reductionist experiments, 
genomics/proteomic data, and clinical care (translational medicine).   
 
In this manner, technological and theoretical advances in computer science and mathematics 
have offered new options to complement experimental study design.  As opposed to in vivo 
studies that are performed in living organisms and in vitro studies that are undertaken using cell 
cultures, in silico studies utilize computational techniques[72,73,74].  The patterns discovered by 
such techniques and the synthesis of experimental data and theoretical concepts allow creation of 
models to explain complex phenomena.  Effective studies of complex systems must be made by 
analysis of the parts (the “omic” tree) followed by a non-linear recombination to model as much 
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of the system as is known at the time[75,76].  In essence, the resulting model must exhibit its 
own emergent properties, allowing science to catch necessary glimpses that provide for the 
creation of new hypotheses. Manipulation of the model will then provide direction to the 
subsequent methodologies necessary to take the next steps in discovery. The computational 
challenge is creating models that contain sufficient elements and power to successfully predict 
how the process will respond to interventions.  To develop useful integrative systems biology 
approaches, complexity theory and its computational tools must be utilized. This complexity 
approach is consistent with the overall NIH Roadmap initiative and specifically with the 
computational biology approach discussed in the initiative 
(http://nihroadmap.nih.gov/bioinformatics).  
 
Ideally, a well-constructed computational model will offer a virtual laboratory to test biological 
hypotheses and therapeutic options prior to testing these theories in vitro or in vivo[77].  The 
ability of any model, from cell cultures to in vivo animal models to mathematical models, to 
make accurate predictions is dependent on the accuracy of the relation between the model and 
the real-world process that is being modeled[78].  This is especially true of mathematical models 
as all the observations are done in silico.  Therefore, such a model will require extensive 
validation in order to prove it is an accurate reflection of the biological process being modeled.   
 
Validation of a mathematical model is focused at two points: the underlying assumptions and the 
behavior of the model.  The validation of the assumptions of the model can be addressed through 
comparing the architecture and rules of the model with what is known about the components of 
the modeled system.  The difficulty lies in verifying the assumptions in the context of the in 
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silico model as all models represent some degree of abstraction.  Validation of the behavior of 
the model consists of comparing the behavior of the model with some real-world data set of 
expected behavior.  When the behavior of the model matches the real-world process, then the 
model is deemed valid for that particular test.   I.E. the plausible validity of the model is based on 
similarity to real world findings.  Conversely, if the model behavior does not match, then the 
model is invalid and must be reevaluated.  Once the model is altered, the model must undergo 
the validation process anew (Figure 4). One problem involves determining the next step when a 
model behavior does not reflect real world behavior.  The lack of fit may be due to calibration or 
to an error in the basic structure of the model; this validation will require extensive literature 
searches to obtain additional mechanistic insight as well as trial and error attempts at 
reconstruction.  
 
The advantages of developing a successful mathematical/computational model cannot be 
overstated.  Scientist will be able to test hypothesis nearly instantaneously.  A successful model 
will target  promising novel therapeutic approaches, thereby improving the success rates of 
clinical studies.  It will also promote the discovery of new therapeutic approaches that come 
directly out of the modeling process.  The time from bench to bedside will be decreased as 
millions of experiments may be run on a model in a very short period of time allowing the 
investigator to choose the best possible intervention strategy prior to any clinical trial[79].  
Intervention strategies may be streamlined and personalized prior to clinical application. 
 
Ordinary differential equations-  ODEs provide a valuable tool for analysis and prediction of 
biological systems over time.  The ODE paradigm is based on a series of equations that describe 
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 Figure 4: Computational Modeling Flow Diagram.  The flow diagram demonstrates the 
iterative process required for creation of a high performance, validated model. 
 
the change in the states of the variables of the system over time[80].  The differential equations 
are derived from a combination of known and hypothesized kinetics of the components of the 
biologic system[81,82].  In general, the equation variables represent average concentrations of 
the various components.  Furthermore, parameters are embedded in the equations that represent 
the state of the system being modeled.  If they are not too complex, a system of ODEs can be 
solved analytically.  Otherwise, they can be solved computationally and analyzed using methods 
from nonlinear analysis to explore the properties of the system.  Because these equations are 
based on biologic interactions, ODE can predict outcomes beyond the range of available data.  
The most valuable aspect of an ODE is the ability to manipulate the variables allowing the 
manipulation of a biologic mechanism and providing an outcome that may be analyzed; thereby, 
allowing in silico experiments and subsequent in vivo experimental validation. 
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 Such a dynamic systems can used to capture the gross behavior of the system.  The advantages of 
using ODE include: 1) the ability to explore properties of the system using non-linear analysis 
techniques 2) prediction of outcomes beyond the range of available data, and 3) manipulation of 
variables to determine the effects on the system.  Unfortunately, there are also disadvantages of 
ODE including: 1) multiple feedback loops lead to equations that are difficult to solve, 2) a 
priori necessity of a complete description of the system, and 3) spatial dynamics are difficult to 
simulate.  
 
Agent Based Modeling - In order to address the shortcomings associated with ODE models, we 
present the application of a computational systems biology approach using agent based modeling 
and simulation (ABMS)[83,84].  ABMS provides a powerful alternative to differential equations.  
ABMS is a relatively new modeling paradigm derived from cellular automata (CA).  CA was 
originally developed by Stanislaw Ulam and John von Neumann and more recently popularized 
by Stephan Wolfram[85,86,87]. CA is an abstract mathematical representation of a machine, 
which can be made to operate on a set of rules.  A CA is a 2-D grid consisting of spaces called 
“cells”.  Each cell is allowed to assume a finite number of states, each of which is determined by 
a pre-defined set of update rules.  A CA update rule is defined as the rule that every CA follows 
that determines its state at the next time step as a function of its current state and the state of its 
neighbors.  Thus, CA are complex systems in that you have large numbers of components with 
no central controller and only local communication.  Such CA may exhibit emergent behaviors 
that cannot be predicted from the CA rule.  ABMS is an extension of CA in that it has mobile 
components that can move through the grid.  
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 ABMs analyze biological systems based on the interactions among its components.  ABMs are 
dynamic systems that are discretized: time, space, and internal state[3,88,89,90].  ABM behavior 
is defined by rules that are a function of their local environment and their state.  ABM models 
are built on a grid of usually square spaces that are capable of entering a finite number of states.  
Each agent is assigned a state with a discrete probability of interacting with agents around it.  
Every agent has the same set of rules for updating its internal state.  Based on the values of its 
neighboring agents and its current state.  At each time step, the rules are applied to the whole 
grid and a new generation of agents is created  
 
ABMs are based on creating rules and defining mechanisms of behavior for the individual 
components of system.  The components of a system are classified into types of agents by virtue 
of shared behavior.  The behavior mechanisms are expressed as a series of conditional rules that 
allow easy conversion into computer programs.  Again the rules are created based on known and 
hypothesized mechanisms.  A simple example would be the creation of an agent that represents 
fibroblasts that when exposed to TGF-B synthesizes collagen.  The model defines a world based 
on defined characteristics and generates populations of the various types of agents.  The agents 
are able to interact based on programmed behaviors that are defined by their rule systems 
initiated by inputs from their environment.  For example, fibroblasts would respond to growth 
factors and cytokines that are secreted by other fibroblasts that they encounter in their immediate 
neighborhood.  In order to mimic real systems, the agents run in a parallel.  The resulting 
dynamics of the system then emerge from the multiple interactions between the agents over time 
rather than dictated by an overlying controller.  This type of modeling is “bottom up,” as all 
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measured output parameters and the resultant outcomes from the model are generated by the 
actions of the individual agents.  One of the advantages of ABM is the intuitive rule based 
definitions that are easily understood by non-mathematicians.  Furthermore the mechanistic rule 
based nature of ABMs allows the simulation of any intervention that deals with a defined 
mechanism. 
 
Agent based modeling is an approach to simulating the behavior of a complex system in which 
agents interact with each other and with their environment through simple local rules.  Again the 
rules will be derived from experimental data as well as literature-mining.  The advantage of such 
a technique include: 1) non linear relationships are easily modeled 2) the model is intuitive and 
does not require higher level mathematics for use and understanding, and 3) flexibility.  The 
disadvantages of agent based modeling include: 1) difficulty with validation 2) large amounts of 
computational power needed for large simulations.   
 
ABMS provide significant advantages over other modeling paradigms when modeling biologic 
systems[79,83,84].  The models are flexible in that changes in agent behavior may be done 
without having to reprogram the whole model.  This flexibility allows a wide range of behaviors 
to be captured.  The coding of such models may be mechanistic based.  Every aspect of how 
agents behave and interact must be explicitly coded.  Additionally, the variables that determine 
the agents‟ behavior must also be defined.  This behavior is usually coded at mechanistic levels 
allowing hypothesis to be easily tested.  The agents are able to adapt and change their behavior 
based on their environment.  As all biological processes are inherently dynamic, the ability of 
such agents to capture the dynamic behavior of systems is critical.  The models are easily 
35
scalable.  Once the behavior of a given agent is defined, inhabiting a system with multiple 
instances is easy.  Therefore, examining the behavior of a system of arbitrary size is more a 
function of computational speed and systems resources rather than ability to generate larger 
models.  One of the greatest strengths of such models is to create virtual experiments.  The 
experiments can be repeated an arbitrary number of times and the data can be analyzed using 
traditional statistics.  This allows direct comparisons between the in silico models and in 
vivo/vitro experimental data.  ABMS allow constructive proofs of systems.  I.E. you create a 
model that generates a behavior. Regardless of in vitro/vivo observation of this behavior, the in 
silico model results imply that there is at least one set of conditions that may create such 
behaviors.  This allows us to grow generative models that capture systems as they are expanded.   
Another important aspect of such models is their ability to run many experiments at a very low 
cost.  Once the model is created, the cost of running such models is usually minimal. 
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Abstract 
 
The complex interactions that characterize acute wound healing have stymied the development 
of effective therapeutic modalities.  The use of computational models holds the promise to 
improve our basic approach to understanding the process.  By modifying an existing ordinary 
differential equation model of systemic inflammation to simulate local wound healing, we expect 
to improve the understanding of the underlying complexities of wound healing and thus allow for 
the development of novel, targeted therapeutic strategies. The modifications in this local acute 
wound healing model include: evolution from a systemic model to a local model, the 
incorporation of fibroblast activity, and the effects of tissue oxygenation.  Using these 
modifications we are able to simulate impaired wound healing in hypoxic wounds with varying 
levels of contamination.  Possible therapeutic targets, such as fibroblast death rate and rate of 
fibroblast recruitment, have been identified by computational analysis.  This model is a step 
towards constructing an integrative systems biology model of human wound healing.  
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Introduction 
A soft tissue injury elicits a well-prescribed wound healing response
1, 2
.  The process of wound 
healing is designed to restore anatomic and functional characteristics of the tissue; however, little 
progress has been made in improving the wound healing response time or in preventing 
complications such as fibrosis, infections, and formation of non-healing wounds
3
.  In this paper, 
we describe a computational model of acute wound healing designed to allow a system-level 
analysis of the wound healing response using ordinary differential equations (ODEs).  As a first 
step to a more comprehensive model, we have explored the combined effects of bacterial 
infections, inflammation, and tissue hypoxia on the rate and success of wound healing since 
these processes are well-known as affecters of healing.  As this model matures, it will provide 
the opportunity to test new mechanisms and novel therapeutic of wound healing strategies in 
silico. 
 
Despite burgeoning interest in the field of computational biology, work of limited scope has been 
published on modeling the acute wound.  Most of these studies demonstrate the difficulties of 
adequately accounting for the myriad of potential interactions
9
.  For example, in their respective 
works on epidermal wound healing, Stekel et al.
10
, Walker et al.
11
 and Morel et al.
12
 do not 
attempt to simulate healing by fibroblasts and do not implement inflammatory changes in their 
models.  Dallon et al.
13
 constructed an ODE model of collagen deposition focusing on the 
fibroblasts and their relationship to the underlying extracellular matrix, but do not account for 
inflammation or repair of underlying tissue damage.  Schugart et al.
14
 recently published a model 
of wound angiogenesis as a function of tissue oxygen tension but the model does not specifically 
address the wound healing process. 
39
 Reynolds et al.
15-16
 created an ODE model designed to simulate inflammation and repair on a 
systemic level in the setting of a systemic insult such as sepsis.  We have modified and extended 
their work to apply it to a local wound.  ODEs provide a valuable tool for analysis and prediction 
of biological systems over time
17
.  ODEs model the changes in important physiological variables 
over time. The equations are derived from a combination of known and hypothesized kinetics of 
the components of the biological system.  In our model, the state variables represent average 
concentrations of the various dynamic components.  Furthermore, parameters are used in the 
equations to account for static components of the system being modeled.  The system is solved 
numerically and the properties of the system can be explored mathematically.  Because these 
equations are based on biological interactions, ODEs can predict outcomes beyond the range of 
available data.  The most valuable aspect of a mathematical model is the ability to manipulate the 
variables and parameters, perform experiments in silico, and examine their results.  The 
biological mechanisms of a wide range of potential situations may then be analyzed together 
with their outcomes.  In vivo validation would then follow from in silico experimentation. 
 
Materials and Methods 
As a first attempt to capture the dynamics of local wound healing over time, a four-variable 
system of ordinary differential equations was developed. The variables in this model represent 
total local tissue (D)amage, (P)athogen level, overall i(N)flammation, and the concentration of 
(F)ibroblasts.  For each of these variables we used known biological interactions to develop a 
differential equation that describes the rate of change for the variable. The interactions included 
in this model are depicted in the model schematic, Figure 1.  
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Figure 1: Model schema that illustrates the interactions between the four variables.  Arrows indicate positive 
feedback and bars indicate negative feedback. 
 
The fundamentals of the model are based on the observations that tissue damage is increased by 
inflammation and hypoxia, while wounds are repaired by fibroblasts
18-21
.  Interpreting the 
interactions in Figure 1, we developed the four variable model, given below in Equations (1)-(4). 
This model was adapted from the four variable model created by Reynolds et al., which is 
included in Appendix A.  
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The difficulties in modeling complex physiologic processes are defining the system variables and 
representing their interactions mathematically.  To address this, we have combined related cell 
types and signaling process together.  As a result, it is not possible to have units on many of the 
biological quantities. Specifically, because tissue damage is complex and involves many 
biological markers, it is a difficult quantity to measure. Thus in this model D has no units.  
Instead, we track the relative changes over time and evaluate healing based on percentage change 
of damage (D), with a return to under 10% damage considered healed.  
 
Pathogen Equation 
In developing Equation (1), the pathogen equation, we made similar assumptions to those used to 
develop the pathogen equation in Reynolds et al.  We assumed that the pathogen population has 
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a growth rate of pgrowth and a carrying capacity of P∞  giving rise to the first term of Equation. 
Unlike the Reynolds et al. model we take into account that the pathogen population is increased 
in low oxygen environments
19
. Therefore, pgrowth is a function of the oxygen level in the local 
environment and determined by the function: 
  
This relationship between tissue oxygenation levels and bacterial growth is illustrated in Figure 
2a. with Ocrit set to 5, which is equivalent to a transcutaneous oxygen level of 30mm Hg
22, 23
. If 
the tissue oxygen level is above the critical value, pgrowth is fixed at 0.3, since the effects of 
hyperbaric oxygen on wound healing are not included in this model.  However, this function 
does capture the increase in anaerobic pathogen reproduction that occurs in hypoxic 
environments. The second term in Equation (1) is directly from the Reynolds et al. model and 
accounts for local immune mediators that immediately interact with the pathogen, such as 
defensins and non-speciﬁc antibodies.  
 
Inflammation recruited to the wound is generally thought to assist in the destruction of pathogens 
and thereby is assumed to decrease pathogen levels, while causing some degree of tissue 
damage
2, 4, 24-26
.  The effect of this process on pathogen level is modeled with the third term of 
Equation (1). We model the depletion of pathogen from an encounter with an inflammatory cell 
with a term of the form 
 
k
pn
N P . However, since fibroblasts modulate the inflammatory 
response by initiating wound repair, N in this term is replaced with  f (N;F) .   
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Figure 2: (a) Dependence of the pathogen growth rate on tissue oxygenation.  Anaerobic pathogen growth rate 
increases at lower oxygen levels. (b) Graph of the function g(O2), illustrating the impact of tissue oxygenation on 
rate of damage increase.  Oxygen levels below the critical level Ocrit promote additional damage, whereas higher 
oxygen levels decrease the rate of damage.  
 
The function  f (N;F)  represents the inhibition of inflammatory cells by fibroblasts.  We use the 
same definition of the function f (N;F)  as in Reynolds et al., since we are modeling the down-
regulation of the same cell population. Including this inhibition produces the third term of 
Equation (1): -kpnf(N; F)P. 
 
Inflammation Equation 
Inflammatory cells are recruited by pathogens, damaged tissue, and other inflammatory cells and 
mediators
21, 25
.  Incorporating this activation of the inflammatory cells into the model we get the 
first term of inflammation equation, Equation (2). First we assume that inflammatory cell 
activation is triggered by the three variables N, D, and P giving a rate of activation of
 
R  k
np
P  k
nn
N  k
nd
D.  As in the pathogen equation, Equation (1), we account for the inhibition 
of inflammation due to the presences of fibroblasts and we replace the basic activation rate with 
one that includes inhibition 
 
R(P, N , D;F)  f (k
np
P k
nn
N  k
nd
D;F) . The process of activation 
occurs on a faster time scale than the other interactions included in this model, this allows us to 
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not explicitly track the resting population of inflammatory cells, and to model activation with the 
sigmoid function 
 
s
nr
R(P, N , D; F )

nr
 R(P, N , D; F )
. Further details on the derivation of this term are in 
Reynolds et al.  
 
Fibroblasts are recruited to the wound by tissue damage and inflammation and are able to repair 
tissue damage and modulate the inflammatory response 
2, 4, 27-29
.  This modulation of the 
inflammatory response is represented with the term 
 

fn
FN in Equation (2). The inflammation 
population will decrease at greater rate when fibroblasts are at a higher level.  
The majority of cell types, such as inflammatory cells and fibroblasts, are not immortal; their 
half-life determines the duration of their efficacy
30, 31
.  Therefore, as traditionally found in most 
ODE models, the half-lives of inflammatory cells and fibroblasts were used to represent the 
average decay rate of a cell
17
.  Incorporating the intrinsic decay of the inflammatory cells we get 
the final term of Equation (2),  
 

n
N . 
 
Damage Equation 
Tissue is damaged not only by the initial wound, but also by the influx of inflammatory cells to 
the wound site during the inflammatory stage of wound healing. To model this dependence of the 
damage level on the inflammation we use ( )dn sk f N . The function fs is a nonlinear function of N, 
because low levels of inflammation are not as effective at inducing tissue damage.  We also 
include inhibition of inflammatory cells in this term. Therefore, in Equation (3), we have the 
term ( ( ; ))dn sk f f N F .  
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The amount of damage that is repaired is proportional to both the current amount of damage and 
the amount of fibroblasts present.  This leads to the term 
df DF in the damage equation, 
Equation (3).  Damage is decreased at a faster rate when fibroblast levels are higher. Also we 
include the term d D  in Equation (3) to model intrinsic tissue repair.  
 
The final term in Equation (3) models the impact of tissue oxygenation O2 level on the rate of 
change of damage.  This impact is described by the function g(O2) (Figure 2b), which is designed 
to capture the increase in damage in hypoxic environments and to represent a small healing 
effect if O2 is larger than the critical value, Ocrit
22. 23
.   
 
 
Fibroblast Equation 
The final equation, Equation (4), models the fibroblast population. We assume in normal skin 
there is a background source of fibroblasts, sf. This gives rise to a baseline level of circulating 
fibroblasts, which exist in both pre-wounded tissue and healed tissue.   
In response to tissue damage and inflammation, the fibroblast population will increase. The 
second term in Equation (4) models this growth when inflammation and/or damage are nonzero. 
The term has the form 
( )
1 ( )
fn fnd
fnd
k N k D
N k D

 
because we assume the dependence of the fibroblast 
population on levels of damage and inflammation is nonlinear. That is, at low levels of 
inflammation and damage the recruitment of fibroblast is slow, while at high levels the process 
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of fibroblast recruitment saturates. As with other terms involving inflammation the process is 
inhibited using the same function, f, so the final form of the term is 
( ; )
1 ( ; )
fn fnd
fnd
k f N k D F
f N k D F

 
. 
As described above, fibroblast have an intrinsic death rate f, and this is modeled by the final 
term of Equation (4),  
f F . 
 
Simulations 
Our model equations were solved numerically using both the software package XPPAUT
32
 
(XPPAUT is a freely available software package for solving differential equations available for 
download at http://www.math.pitt.edu/~bard/xpp/xpp.html) and several of our own 
independently developed C++ computer programs.  A list of baseline parameters is included in 
Table 1 for reference.  The parameters were derived from experimental values found in the 
literature or estimated such that the system behaved in a biologically appropriate manner
15, 22, 23
.  
We performed several in silico experiments to investigate the effects of (i) varying the amount of 
initial damage, D(0), and the initial pathogen levels, P(0), and (ii) varying certain parameters 
such as the tissue oxygenation level O2 and the rate of fibroblast recruitment sf.   
 
In each experiment, we simulated two weeks of the wound healing process (336 hours) after the 
initial wound insult in order to observe more of the transient effects en route to steady state
33
.  
Two weeks provides an adequate amount of time for normal wounds to heal.  The resulting end 
state of the wound was categorized as one of three types:  
 Healed if the damage is decreased by 90% within 2 weeks (i.e. for D(0)=10, damage is 
less than 1 after 2 weeks); 
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 Non-healing wound if damage remains higher than 10% of initial damage and pathogen 
levels decrease to zero (i.e. for D(0)=10, P(0)>0, damage is greater than 1 but pathogens 
are nonexistent after 2 weeks); and 
 Chronic infection if both damage and pathogen levels remain at above 10% of their initial 
levels after 2 weeks (i.e. for D(0) =10, P(0) = 1, damage is greater than 1 and pathogen is 
greater than 0.1 after 2 weeks). 
The non-healing wounds as defined above correlate clinically to wounds in which there is 
impaired wound healing, but are not infected
2-4, 24, 34, 35
.  Chronic infections as defined above 
correlate clinically to wounds that are infected and are thereby unable to heal normally
2-4, 34, 35
. 
 
Results 
All simulations started immediately after the wound formation.  In the model, this translated to 
no initial inflammation (N(0)=0) and to the initial level of fibroblasts at a normal background 
level (F(0)=0.1).  Initial damage and initial pathogen levels were set to represent different injury 
scenarios.  Unless otherwise specified, all parameter values were set to their baseline values 
(Table 1). 
 
Figure 3 is the baseline simulation and shows normal healing behavior in a small, 
uncontaminated wound with normal perfusion (D(0) =0.2 and P(0) = 0).  As expected, this type 
of wound elicits a brief period of a slightly elevated inflammatory response and an increase in 
fibroblast level.  This scenario results in normal healing of the wound, which is represented by 
the damage variable decreases to zero within two weeks.     
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Figure 3:  Healing behavior of a small, “clean” wound (D(0) = 0.2, N(0) = 0, F(0) = 0.1, and P(0) = 0).  (b) 
Inflammation peaks within two days after initial insult, and decays to 0 within two weeks.  (c) Damage steadily 
decreases, and after two days the amount of wound damage is approximately half its initial amount.  (d) Fibroblasts 
peak three to four days after initial insult, and then return to their baseline value within two weeks. 
 
The first experiment focused on increasing the initial wound size (D(0) = 2; 10-fold increase 
from Figure 3) while leaving pathogen levels at zero (P(0) = 0).  Figure 4 illustrates the effect of 
this change on the behavior of the wound.   The significantly increased initial wound size, leads 
to a non-healed wound at two weeks where damage, fibroblasts, and inflammation all plateau at 
an elevated level.  This correlates clinically to large acute wounds that require prolonged healing 
times and are at increased risk for developing infections
4, 36
.   
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Figure 4:  Non-healing wound of large initial size and no initial pathogens (D(0) = 2, N(0) = 0, F(0) = 0.1, and P(0) 
= 0).  (a) The pathogen level remains at 0 for the duration of the simulation.  (b-d) Inflammation, damage, and 
fibroblast levels plateau at elevated levels, and the wound persists even after two weeks.  
 
 
Figure 5 shows the impact of tissue oxygenation levels on wound healing behavior by plotting 
the pathogen and damage levels for three different levels of O2. For each level of oxygenation 
the wound has a moderate initial size and pathogen level (D(0) = 0.5 and P(0) = 0.3).  All 
parameters except O2 were held at their baseline values.  If the tissue oxygenation is at the 
borderline level (O2 = O2crit=5.0; equivalent to a transcutaneous oxygen level of 30mm Hg
22, 23
), 
the wound begins to heal after a two-day transient period during which the amount of tissue 
damage increases in size as a result of the inflammatory response (Figure 5 a,b).  
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 Figure 5:  Transients for pathogen and damage with various O2 values. For all three O2 values the initial conditions 
used were D(0) = 0.5, N(0) = 0, F(0) = 0.1, and P(0) = 0.3. (a) and (b): are the pathogen and damage transients, 
respectively, for a O2 value of 5, which is the value of O2crit. (c) and (d): the pathogen and damage transients, 
respectively, for a O2 value of 4.0, which results in a non-healing wound.  (e) and (f) : the pathogen and damage 
transients, respectively, for a O2 value of 2.5, which results in a chronic infection.   
 
Both the damage and inflammation return to zero and the fibroblasts are decreasing toward their 
background level by the end of two weeks. We also simulated the same wound in a reduced 
oxygen environment, where O2 is below the critical level (O2 = 4.0), which leads to significant 
impairment in wound healing (Figure 5 c,d).  The pathogens are successfully removed, but 
damage persists beyond two weeks.  Finally, if the tissue oxygenation is further lowered (O2 = 
2.5), both pathogens and damage plateau at an elevated level, corresponding to chronic infection 
(Figure 5 e,f).  These represent the types of non-healing wounds, both infected and non-infected, 
seen in patients with vascular insufficiency
2, 37
. 
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In a third experiment, we investigated the combined effect of tissue oxygenation (O2) and 
f ) on the wound healing behavior, leaving all other parameters at their 
baseline values.  By increasing the fibroblast mortality rate, we simulated the premature 
senescence of fibroblasts observed in older patients and diseases such as diabetes mellitus
4, 36, 38
.  
Figure 6 illustrates the wound healing behavior for different choices of initial conditions.  In 
Figure 6a, the initial damage and pathogen levels are low (D(0) = 0.2 and P(0) = 0.2), and the 
wound always heals within two weeks if O2 > Ocrit f = 
0.01).  If the f > 0.14), the high mortality of 
fibroblasts invariably results in a non-healing wound.  In hypoxic environments, we observe non-
healing wounds even when fibroblast mortality is low as a direct result from tissue necrosis.  
Figure 6b shows the impact of doubling the initial pathogen level (P(0) =0.4).  In this case, both 
the regions of non-healing wound and chronic infection become substantially larger. 
 
 
 
 
 
Figure 6:  Long-term wound behavior for various choices of tissue oxygenation O2 and fibroblast mortality (μf) ( 
N(0) = 0 and F(0) = 0.1).  (a) A wound with initial damage D(0) = 0.2 and pathogen level P(0) = 0.2.  Large 
fibroblast mortality always leads to non-healing wound.  If the fibroblast mortality is lower, then we observe chronic 
infection in hypoxic environments and healing if tissue oxygenation is appropriately large.  (b) If the initial pathogen 
level is doubled to P(0) = 0.4, the regions of chronic infection and non-healing wound are substantially larger, and 
the wound is unable to heal within 2 weeks time. Simulations were not run for fibroblast half-life values less than 12 
hours (marked by the dashed lines in each plot), since values below this level are typically unseen.  
 
To understand if an advanced therapy might impact wound outcome, we designed an in silico 
experiment to investigate the possible impact by varying the rate of fibroblast recruitment (sf), 
and analyzed the long-term healing behavior.  We simulated the first two weeks after initial 
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insult for a wound with baseline initial conditions D(0) = 0.5, N(0) = 0, F(0) = 0.1, and P(0) = 0, 
for all parameters except fibroblast recruitment (sf).  For larger recruitment rates (sf > 0.012), the 
wound heals within two weeks, whereas a non-healing wound results if recruitment is impaired 
(sf < 0.011).  Increasing sf, i.e. recruiting more fibroblasts, has a strong impact on the overall 
healing time.  For example, if sf = 0.001, the wound requires 158.2 hours to shrink to 10% of its 
original size, as compared to 139.0 hours if sf is doubled to 0.002 (Figure 7).  
 
 
 
 
 
 
 
 
 
Figure 7:  Comparison of damage vs. time for different fibroblast recruitment rates (D(0) = 0.5, N(0) = 0, F(0) = 
0.1, and P(0) = 0). The dashed curve is damage transient for the baseline fibroblast recruitment rate, sf = 0.001. The 
solid curve is the damage transient with the same initial conditions and a fibroblast recruitment rate twice baseline, sf 
= 0.002.  
 
By doubling sf, the healing time decreases by about 12%.  The maximum amount of damage, 
which accumulated as the wound healed, decreased by 11%. Furthermore, when sf=0.002 the 
influx of inflammation to the wound site did not elicit more damage than the initial level of 
D=0.5. These experiments correlate to the use of agents such as recombinant PDGF
39
 and basic 
fibroblast growth factor, bFGF
40
. The Akita et al.
40
 study reported a 20% decrease in healing 
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time with the use of bFGF, which is on the same order of magnitude as the decrease seen our 
model experiment. 
 
Discussion: 
Mathematical models offer a non-invasive intermediary step between animal models and human 
subject studies that allows hypotheses and therapies to be tested prior to clinical studies.  An in 
silico model would potentially increase the success rate of clinical trials or aid in designing more 
appropriate animal studies.  These animal or clinical studies would then in turn, validate the 
model.   
 
As an initial step to creating such a model, we have modified an ODE model of the acute wound 
healing response to a soft tissue injury.  The model includes factors such as bacterial 
contamination and wound oxygenation. Assuming normal conditions, our model predicts the 
typical progression of healing behavior for a wound.  The ODE model was also able to 
successfully simulate the impairment in wound healing found in a hypoxic wound environment 
and a contaminated wound.  With extremely low levels of oxygen, our model predicts a chronic 
infection where the wound does not heal and pathogens persist in the wound.  Both of these 
states are well documented clinically
35, 38
. 
 
We also examined the situation of elevated and depressed fibroblasts mortality rates.  Clinically, 
instances of elevated fibroblast mortality are seen in diabetic and elderly patients.  Here we saw 
that with high rates of fibroblast mortality the wound cannot heal.  Additionally, a scenario of 
moderately low fibroblast mortality and high initial pathogen levels predicts the state of chronic 
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infection.  Finally, we examined the case where fibroblast production is either impaired or 
enhanced.  Impaired fibroblast production results in a non-healing state, but under conditions 
where the production is increased we have wounds that heal at notably faster rates.  This 
provides a framework from which to test a new hypothesis in a living model. 
 
The present study represents only a first step toward developing a detailed mathematical model 
of acute wound healing.  Consequently, there are many opportunities for improving upon our 
existing model; these include, 
 With the exception of time t, all quantities are measured in arbitrary units.  By expanding 
the model to include variables that represent specific cell types and mediators one may 
estimate parameter values and assign physiologically meaningful units.  
 In its present form, our model does not incorporate time delays.  This prevents the 
simulation of the time lags inherent in signaling pathways as well as in fibroblast 
recruitment after the onset of inflammation. 
 We did not attempt an exhaustive study of the impact of individual parameters on long-
term healing behavior.  Although we chose to focus on parameters such as the production 
and death rates of fibroblasts, it is likely that other parameters have a profound impact on 
healing. 
 We focused on strongly interlinked local factors (inflammation, fibroblast function and 
recruitment, bacterial contamination, and tissue oxygenation) with resultant dynamic 
non-linear behaviors.  Factors such as depth and shape of the wound, wound contraction, 
epithelization, and angiogenesis have not been addressed. 
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 We have not included systemic effects on wound healing, e.g., nutritional status, age, sex, 
and underlying comorbidities. 
 
Despite the limitations inherent in our model, it does demonstrate the to use a systems biology 
approach to human wound healing.   Mathematical models show great potential as a platform for 
hypothesis generation and experimentation prior to further refinement in vitro and in vivo.  A 
refined method of computational analysis would decrease overall cost, time, and need for 
invasive testing.  In the future, we hope to further elucidate the process of inflammation, 
epithelization, contraction, angiogenesis, and systemic effects, in order to create a model that 
more closely corresponds to the actual wound environment.  Because our simplified model 
produces qualitatively reasonable results, we are optimistic that including systemic effects will 
enhance our understanding of the acute wound-healing process, ultimately leading to improved 
clinical therapies. 
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Table 1.  Baseline parameter values.  * denotes estimated parameter 
Parameter Value Comments 
kpm 0.6 Rate at which inflammatory cells kill pathogen 
nonspecifically
*
.
 
 
kpn 0.6 Rate at which inflammatory cells kill pathogen by 
phagocytosis
15
. 
µn 0.05 Half-life of activated inflammatory cells
15
. 
F∞
 
0.30 Maximum fibroblast density
*
. 
kmp 0.01 Rate at which non-specific inflammatory response is 
exhausted by pathogens
*
. 
knp 0.1 Rate of activation of inflammatory cells by pathogens
*
. 
knd 0.015 Rate of activation of inflammatory cells by damaged tissue
*
. 
sf
 0.001 Rate of fibroblast recruitment
*
. 
sm
 
0.005 Rate of inflammatory cell recruitment
*
. 
knn 0.01 Rate of activation of inflammatory cells by activated 
inflammatory cells
*
. 
kdn 0.35 Maximum rate of damage by activated inflammatory cells
*
. 
kfn 0.004 Rate of fibroblast recruitment by inflammatory cells
*
. 
kpg 0.55 Rate of pathogen growth
15
. 
snr 0.08 Rate of inflammatory cell recruitment
*
. 
xdn
 
0.1 Level of inflammatory cells needed to bring damage to half 
its maximum
*
. 
kfnd
 
48 Effectiveness of tissue damage and inflammatory cells to 
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recruit fibroblasts
15
. 
P∞
 
20 Maximum pathogen density
15
. 
µnr
 
0.12 Half-life of inactivated inflammatory cells
15
. 
µd
 
0.02 Baseline damage repair rate
15
. 
µf
 
0.01 Half-life of the fibroblasts
*
. 
µm 0.002 Half-life of non specific inflammation
15
. 
µdf 0.002 Determines the amount of damage healed per unit damage 
per fibroblast
*
. 
µfn 0.002 Determines that anti-inflammatory effects of fibroblasts
*
. 
α 0.1 Along with µd, determines the amount of damage inflicted 
by hypoxia
*
. 
xd
 
2 Along with βd determines the rate of tissue damage caused 
by hypoxia*. 
βp 0.3 Along with O2/ Ocrit ratio, determines the increase in 
anaerobic reproduction rate induced by hypoxic conditions
*
. 
βd 0.3 Determines the rate of tissue damage caused by hypoxia*. 
Ocrit 5 Critical oxygen level below which wound healing is 
impaired.  Equivalent to a transcutaneous oxygen level of 
30mm Hg
22, 23
. 
O2 User 
Defined 
Level of tissue oxygenation. 
*Estimated parameter 
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Appendix A 
 
The original equations from Reynolds et al.
15
 are:
 
 
*1 ( )
pm m
pg pn
m mp
k s PdP P
k P k f N P
dt P k P
 
    
   
*
*nr
n
nr
s RdN
N
dt R


 

 
*( ( ))dn s d
dD
k f f N D
dt
 
 
*
*
( )
1 ( )
cn cndA
c c A
cnd
k f N k DdC
s C
dt f N k D


  
 
 
( )np nn ndR f k P k N k D    
2
( , )
1 ( / )
A
A A
V
f V C
C C 


 
CA represents the amount of system anti-inflammatory mediator. The parameters sc, kcn and kcnd 
correspond to Sf, Kfn, and Kfnd, respectively. N
*
 represents inflammation and all other variables 
and parameters are represented by the same notation as used in our model.   
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Abstract: 
The coagulation and fibrinolytic systems are complex, inter-connected biological 
systems with major physiological roles. The complex, nonlinear multi-point relationships 
between the molecular and cellular constituents of two systems render a 
comprehensive and simultaneous study of the system at the microscopic and 
macroscopic level  a significant challenge.   We present an Agent Based Modeling and 
Simulation (ABMS) approach for simulating these complex interactions. Our ABMS 
approach utilizes a set of 106 rules to define the interactions among the 59 enzymes 
and factors of the coagulation/fibrinolysis (CF) system interacting with each other in a 
dynamic manner.  These rules simulate the interaction of each “agent”, such as 
substrates, enzymes, and cofactors, on a two-dimensional grid.  This ABMS method 
successfully reproduces the initiation, propagation, and termination of blood clot 
formation and its lysis in vitro due to the activation of either the intrinsic or extrinsic 
pathways. Furthermore, the ABMS was able to simulate the pharmacological effects of 
two clinically used anticoagulants, warfarin and heparin, as well as the physiological 
effect of an enzyme deficiency/dysfunction, i.e., hemophilia and antithrombin III-heparin 
binding impairment, on the coagulation system.  The results of the model compare 
favorably with in vitro experimental data under both physiologic and pathophysiologic 
conditions which assist in substantiating the model.   
 
Introduction: 
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The coagulation and fibrinolytic systems maintain a constant, delicate balance between 
thrombotic response to acute blood loss versus the requirement of the vascular system 
to allow constant blood flow.  Zymogen to enzyme conversions throughout these two 
cascades generates the proteolytic enzymes, thrombin and fibrin, that catalyzes the 
deposition and removal of fibrin respectively. Disruption of this equilibrium results in 
thrombotic events (e.g. pulmonary embolus) versus hemorrhagic events stemming from 
underlying coagulopathies (e.g. vonWillebrand's disease)1  
 
 In the event of an injury to the endothelium, the coagulation system balances the need 
for localized clot formation against the need to prevent system wide activation.  This 
finely tuned system is composed of an assortment of molecular and cellular “agents” 
(e.g. substrates, enzymes, cofactors, inhibitors, platelets, and endothelial cells which 
interact to generate a stable clot in order to rapidly obtain hemostasis.  The new cellular 
model of hemostasis proposes that the classical pathways of coagulation, i.e., the 
intrinsic and extrinsic pathways, mediate on specific cell surfaces in a tightly regulated 
manner. In this model, activation of factor VII (extrinsic, Fig. 1) and factor XII (intrinsic, 
Fig. 1) result in the formation of multi-molecular complexes, the tenase and 
prothrombinase complexes, which eventually generate thrombin. Thrombin then cleaves 
fibrinogen to form fibrin monomers, which polymerize to form a three-dimensional clot.  
Following repair of the underlying damage to the endothelium, the fibrinolytic system 
acts to dissolve the pre-formed clot.  Fibrinolysis is achieved primarily through the 
proteolytic action of plasmin on fibrin polymers that reinforce and maintain the integrity 
of a thrombus (Fig 2). 
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Clot formation is regulated in vivo primarily through the antithrombin III-heparin (AT-H), 
activated protein C (aPC), and tissue factor inhibitor (TFPI) pathways (Fig. 1)2. These 
regulating systems limit the excessive formation of cross-linked fibrin under hemostatic 
conditions.  Similarly, anti-plasmin (AP), plasminogen activation inhibitor (PAI), and 
thrombin activatable fibrinolysis inhibition pathways prevent clot lysis until coagulation is 
complete (Fig 2).  
The specificity of interactions, both molecular and cellular, involved in these complex 
processes supports the concept that the CF system displays global effects through 
emergence of localized events.  The CF system may be viewed as a multi-component 
molecular machine6, in which individual components are linked through multiple 
feedback and feedforward loops.  This introduces non-linear relationships among the 
components. A static diagram such as the classically portrayed coagulation pathway 
Figure 1: Coagulation Cascade and Inhibitors- Inhibitors denoted by circles.  The intrinsic pathway is initiated by 
Prekallikrein or XII.  The extrinsic pathway is initiated by TF.  The intrinsic and extrinsic pathways join at the 
common pathway that begins after Factor X activation.  AT, TFPI, and aPC are the three inhibitory pathways.   
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(Figure 1) cannot adequately describe this dynamic evolutionary network. Moreover, the 
effects of several disease states on the imbalances in the CF system are difficult to 
understand.  For example, the influence of diseases that favor coagulation (e.g. 
coronary artery disease, disseminated intravascular coagulation, cerebrovascular 
accidents, and venous thrombosis), or those that impair coagulation (e.g. hemophilias, 
thrombocytopenias, and von Willebrand disease) remain poorly characterized in terms 
of the interactions of all components in the system over time. 
 
 
 
 
 
 
 
 
To date, most computational models of the coagulation system have focused on using 
ordinary or partial differential equations (ODEs and PDEs) 15-18.  The differential 
equations describe the change in the states of the variables of the system over time and 
are derived from known or hypothesized kinetics.  ODE models can readily simulate 
coagulation in vitro as it is a relatively homogenous system3-5;  however, such models 
face significant limitations when modeling in vivo hemostasis because of complicating 
factors such as non-stationarity, spatial heterogeneity and the effects of blood flow6. 
Therefore, derivation of differential equations suitable for in vivo modeling becomes 
Figure 2: Fibrinolytic Cascade and Inhibitors-  Inhibitors are denoted by circles.  The fibrinolytic pathway is 
initiated by tPA activation of Plasminogen.  Plasmin hydrolyzes fibrin.  Plasmin and fibrin catalyze the conversion 
of Plasminogen to Plasmin. 
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problematic.  Additionally, these models are incapable of demonstrating the 
randomness and variability within the system as it normally operates. 
  
In order to address the shortcomings associated with ODE models, we present the 
application of a computational systems biology approach using agent-based modeling 
and simulation (ABMS) to understand the CF system and predict selected outcomes.  
ABMS provides a powerful alternative to differential equations7-9.  ABMS is a relatively 
new modeling paradigm derived from cellular automata (CA)10, 11.  ABMS has mobile 
autonomous entities (agents) that can move through a 2-D grid.  Each agent is allowed 
to assume a finite number of states, determined by a pre-defined set of rules. Every 
agent is individually updated at the end of each operating period according to the pre-
set rules. The rules are a function of the current state of the agent and the state of its 
neighbors.     
 
As a first step, we created a model designed to simulate the in vitro environment.  The 
goal of the model is to simulate common lab tests performed on patients. 
Materials and Methods: 
In this in vitro model all substrates, reactions, and products from the intrinsic, extrinsic, 
common, fibrinolytic, AT-H, TFPI, PC, AP, PAI, and TAFI pathways have been included.  
In order to create realistic simulations, physiologic concentrations of factors were used 
in the in silico experiments.  The rates associated with the reactions were taken from 
the literature and were assumed to be performed in saturating phospholipid and calcium 
conditions.  The simulations were designed to test experimental conditions that create 
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interesting thrombin profiles or to demonstrate perturbations associated with pathology 
or pharmaceutical agents associated with the system.  
The ABMS approach utilized in this paper uses a two dimensional particle system.  The 
particle model is one in which particles or ‟agents‟ are able to move about and interact 
on a discrete spatial grid.  In this case, the agents of the system are the reactants, 
enzymes, and products, as defined in the entity table (Appendix 1).  Each agent‟s 
location on the spatial grid is defined in a two dimensional grid where the agent‟s 
location is determined by its x and y coordinates.  Each coordinate pair (x, y) is defined 
as a unique grid location.  Multiple agents may occupy a grid location.  A total of 6,241 
grid locations (Figure 3) were used in the coagulation simulations and 321 for the 
fibrinolytic simulations.  A unit time step of the simulation represents 0.01 seconds.   
 
 
 
 
 
 
 
 
 
 
Each grid location of the ABMS can be empty or can be occupied by one or more 
agents .  The neighborhood of each agent was defined as all agents located in the 
Figure 3: Spatial Grid - The spatial grid is three dimensional in that multiple agents are able to inhabit the same 
location. 
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same grid location.  After each time step, an agent was afforded complete freedom to 
move in a random manner to one of the adjacent cells.  The movement of each agent, 
its joining, association, and dissociation with its neighbors are governed by probability 
rules.  The movement parameter determines the extent of movement (0 implies every 
cell is stationary).  The joining-association parameter determines the extent of a given 
agent interacting with an adjoining agent.   The breaking parameter determines the 
extent of disruption of con-joined agents . The joining- breaking interactions were 
defined by the kinetics of the chemical equations that define the agents‟ behavior 
(Appendix 2).   
 
ABMS of Coagulation – To simulate the coagulation phenomenon in vitro  the 
probability of each  interaction event has to be assigned based on biochemical 
properties.  Each coagulation event is an enzymatic reaction with typical affinities in the 
nanomolar to sub-nanomolar range. These high affinities imply that the probability of 
conversion is directly correlated to the kinetics of the reactions. The movement 
parameter is set at one for every agent in the simulations which means they are free to 
diffuse across the grid.  The initial configuration of ABMS contained a pre-defined 
number of agents for the initial reactants , which is proportional to the known 
concentration of agent under normal physiologic conditions. For example, 340,000 
antithrombin agents were utilized corresponding to its 3.4 M concentration in normal 
plasma. Likewise, 30 agents of VIII were present at initial conditions corresponding to its 
physiologic concentration of 0.3 nM. These agents were randomly distributed on the 2-D 
grid at time t=0.  
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Both the prothrombinase and tenase complexes are formed through a combination of 
three factors in vivo. For example, prothrombinase complex is formed by a 
combination of prothrombin, factor Xa and factor Va, while the intrinsic tenase complex 
is formed when factors VIIIa and IXa combine with factor X. These three body 
complexes are not directly simulated in ABMS, as in vivo, these complexes must arise 
through sequential combination of two molecules and thus, we utilized a sequential two-
body collision approach to generate each complex.  
 
 
 
 
 
 
 
 
 
 
 
The spatial grid is in the shape of a square  allowing the agents to interact and bounce 
off the edge of the grid. The system was acellular with complete absence of platelets, 
RBC, or WBC representing plasma that is used in coagulation/fibrinolysis assays.  The 
reactions and rate constants represented by the rule table are representative of 
Figure 4: Computational Algorithm- The simple computational algorithm that controls the flow of the simulations. 
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experimentally observed rates under saturating phospholipid and calcium 
concentrations.  Figure 4 illustrates the algorithm used for running the simulations. 
 
Computational Hardware and Software – A software package designed to run ABMS 
was utilized to design and perform the simulations (Netlogov4.0412).  The user 
determines the subset of, reactions, reactants and coagulation factors, the probabilities 
of reactions, initial agent concentrations, and termination conditions for each simulation.  
The concentration of every coagulation factor was stored every 100 time steps (1 virtual 
second). All simulations were carried out on an Intel based desktop personal computer 
running Microsoft Windows XP.  Because of the nature of the software and the large 
number of interactions, each simulation took between 1-72 hours depending on the 
initial and stop conditions.   
 
Coagulation Simulations – Unless otherwise stated, modeling of the system was 
performed under conditions that simulated the mean physiologic concentrations of each 
soluble factor involved in the cascade, which were derived from literature reports 
(Appendix 3).  The model was designed to simulate volumes of 2mL using 6241 grid 
locations.  The model was tested under 1) conditions in which the type of agents was 
limited to a small subset of the coagulation factors or 2) conditions in which all the 
coagulation factors were represented.  The simulations were designed to test 
experimental conditions that demonstrate pathology associated with the system.  Each 
simulation was run ten times.  Comparisons between the ABMS output and 
experimental data were used to determine the validity of the system.   
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Both PT and aPTT experiments were terminated when 99% of the initial fibrinogen was 
converted to fibrin monomers.  When running PT experiments, an additional end 
condition of 135 seconds was defined.  This time equates to an INR > 10 which is a 
commonly reported value in clinical laboratories.  Similarly, an end condition of 150 
seconds was defined for aPTT experiments. 
 
Fibrinolysis Simulations – Unless otherwise stated, modeling of the system was 
performed under conditions that simulated the mean physiologic concentrations of each 
soluble factor involved in fibrinolysis, which were derived from literature reports in 
human blood under normal physiological conditions (Appendix 3).  Fibrinolysis 
experiments are typically done on volumes of 100µL which corresponds to 321 grid 
locations.  The model was tested under conditions in which the type of agents was 
limited to a small subset of the CF factors.  Given the time scale of hours rather than 
minutes, each simulation was run five times.  Comparisons between the ABMS output 
and experimental data were used to determine the validity of the system.   
 
Simulations - Simulating the CF system is challenging because not all interactions have 
been fully defined. Further, whether ABMS technology can reliably predict the functional 
behavior of the CF system has not been established. Thus, to establish that validity of 
ABMS in understanding the CF system, three sets of simulations were performed. The 
first set of experiments tested the applicability of the CF model. The second set of 
experiments attempted to simulate perturbations of these pathways so as to mimic 
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clinical disease states by measuring prothrombin time (PT) and activated partial 
thromboplastin time (aPTT). Finally, the third set of experiments measured the effects of 
pharmaceutical agents upon these CF pathways 
 
Statistical Analysis –The statistical package R v2.7.0 was used for all statistical 
calculations.  All confidence intervals in the paper are at the 95% level. 
 
Results: 
Three sets of simulations were performed to: 1) Validate the model using previously 
published data and known in vivo and in vitro conditions associated with the intrinsic, 
extrinsic, common pathway, and fibrinolysis; 2) Simulate perturbations of pathways 
mimicking clinical disease states by measuring prothrombin time (PT) and activated 
partial thromboplastin time (aPTT) as well as; 3) Measure the effects of pharmaceutical 
agents upon these pathways. 
 
Model Validation Simulations - Model validation was performed through the first set of 
simulations.  Through successful reproductions of the in vitro experiments performed by 
van‟t Veer et al.13, 14, Wang et al.15, Christensen et al.16, Masson et al.17, Bajzar et al.1  
and in silico experiments performed by Hockin et al.18 as described below, the behavior 
of the ABMS was validated.   
 
Simulation of the Extrinsic Pathway Without Regulation - The intrinsic and extrinsic 
pathways can function independently of each other to generate a clot. In vivo, the most 
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important pathway for the initiation of clot formation is the extrinsic pathway (abnormally 
low levels of PK, HMWK, or XII have no effects on bleeding times); therefore the initial 
simulations are focused on validating the behavior of the extrinsic pathway.  To validate 
the use of ABMS in predicting the functional property of the extrinsic pathway, only 
seven agents were introduced on the rectangular grid including TF-VIIa, V, VIII, IX, X, 
TFPI, AT, and PC.  TF-VIIa complex initiates coagulation resulting in the formation of 
factor IIa, the level of which is proportional to the level of clot formation under normal 
conditions.  TFPI, AT, and PC were used to assess the ability of ABMS to reflect system 
regulation. 
 
The first simulation was performed in the context of the procoagulants (TF-VIIa, II, V, 
VIII, IX, and X).  Formation of thrombin was initiated by TF-VIIa at various 
concentrations (5pM, 30pM, and 130pM).  At each concentration of TF-VIIa, the most 
notable characteristic of the procoagulant simulation (Figure 5a) is its biphasic behavior 
composed of an initiation phase followed by a propagation phase.  This sigmoidal 
growth profile is characteristic of multi-step reactions. The increasing concentrations of 
TF-VIIa resulted in shortening initiation times, arbitrarily defined as the time needed to 
form 20 nM of IIa (Table 1).  Additionally, an increased maximum rate of IIa formation 
during the propagation phase was observed as a function of concentration (Table 2).  
The sigmoidal factor IIa growth profile coupled with a dependence on initiator 
concentration suggest that ABMS may be expected to simulate the coagulation 
cascade*. 
*Elimination of rules 33 or 27, which relate to the generation of thrombin from Xa and generation of Xa from TF-VIIa, 
respectively, suppressed all thrombin formation under all conditions (data not shown). 
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Table 1: Initiation phase length (s).  Initiation time is defined as the time it takes to form 20nM of IIa.  The 
initiation time is a function of the TF-VIIa initiating concentration.  The combinations of TFPI and AT have the 
largest effect on the initiation times. 
 5pM 30pM 130pM 
NI 38.7+/-7.06 20.7+/-2.31 11.8+/-1.57 
TFPI 74.5+/-21.04 39.1+/-10.38 16.2+/-4.11 
AT 59.7+/-10.75 27.9+/-4.44 14.6+/-3.20 
TFPI + AT N/A 50.8+/-13.83 34.2+/-13.04 
 
 
 
Table 2: Maximum thrombin generation rate (nM IIa /s).  The maximal rate is a function of the TF-VIIa 
initiating concentration.  The combinations of TFPI and AT have the largest effect on thrombin generation rates. 
 5pM 30pM 130pM 
NI 43.8+/-6.22 82.7+/-3.50 110.3+/-6.54 
TFPI 30.2+/-5.46 41.0+/-5.24 68.5+/-9.16 
AT 19.1+/-5.80 47.0+/-6.03 85.9+/-5.92 
TFPI + AT 0.7+/-1.48 13.4+/-3.53 37.4+/-7.55 
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Simulation of the Extrinsic Pathway With Regulation- To assess whether ABMS 
simulates the regulatory aspects of coagulation, we examined the behavior of the 
system in the presence of TFPI, AT, and PC.  When TFPI at 2.5 nM (TFPI‟s normal 
plasma concentration) is added to the titrations observed in Figure 5a, a significant 
extension of the initiation phase is observed with only small effect on the maximal rate 
of propagation.  As seen experimentally, adding TFPI to samples with TF-VIIa below 
100pM leads to a doubling of the initiation time (Figure 5b, Tables 1&2).  It is important 
to note that addition of TFPI as the only regulator of the extrinsic pathway does not alter 
the final level of factor IIa, and hence the clot, formed in the process.   
Figure 5: Total thrombin generation with and without inhibitors.  A-C: The initiating concentrations of TF-
VIIa illustrated: circle = 130 pM, triangle =  30 pM, and square = 5 pM.  A) No inhibitors present B) 2.5nM TFPI 
present C) AT 3.4µM present D) The initiating concentration of TF-VIIa is 5pM in the presence of 65nM PC.  TM 
concentration: circle = 0 pm, triangle = 0.1pm and square = 10pm.  N=10. 
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To assess the effect of adding an irreversible coagulation inhibitor, AT was introduced  
at a concentration of 3.4 M (AT‟s normal plasma concentration) to the titrations 
observed in Figure 5a.  The addition of AT leads to formation of characteristic bell 
shaped curves for the formation of IIa at all concentrations (Figure 5c).  These profiles 
are similar to those found in studies of coagulation in plasma.  The AT has little effect on 
either the initiation time rate or the maximal rate of thrombin generation during the 
propagation phase at 130pM concentrations of TF-VIIa (Tables 1&2) suggesting that AT 
alone is an effective regulator of coagulation primarily at low levels of TF-VIIa.  This is in 
line with experiments in plasma, which show that AT is not effective in rapidly reducing 
a bolus of factor IIa stemming from its slow kinetics.   
 
The last important inhibitor for the coagulation system is PC.  Figure 5d demonstrates 
the effects of 65 nm PC and TM on the thrombin generated by the extrinsic system.  
Starting with an initial concentration of 5pM TF-VIIa, thrombin is plotted against time as 
TM concentration is varied (0, 0.1, and 10 nm).  PC in the absence of TM and at low TM 
concentration has minimal effects.  At high concentrations of TM, the rate of thrombin 
generation during the propagation phase is decreased.  Furthermore, a significant 
interruption of the propagation phase occurs leading to a biphasic propagation phase; 
thus, activation following thrombin generation illustrates the dynamic feedback 
characteristic of the PC pathway.   
 
77
  
Simulation of Hyper Anticoagulation - To assess whether a pro-thrombotic state can be 
reliably controlled by either of the two natural regulators, the concentrations of AT and 
TFPI were increased to levels dramatically higher than normal at a fixed TF-VIIa 
concentration (130pM).  Figure 6a demonstrates the effects of increased concentrations 
of TFPI on IIa formation from 1.25 nM (½ baseline) up to 25 nM (20x baseline).  There 
is a progressive elongation of the initiation times with only minimal decrease in reaction 
rates.  The maximal levels of IIa reached for all concentrations of TFPI is the same 
suggesting that even a 20-fold increase in TFPI is not able to shut down the pro-
coagulant signal. On the contrary, increasing AT concentrations from 1.7 M (½ 
baseline) up to 20.4 M (6x baseline) does not alter the initiation time dramatically (Fig. 
6b), but essentially shuts off the pro-coagulant signal. As AT concentrations increase, 
the total amount of IIa generated decreases.  Initiation times and maximal IIa rate are 
decreased as well.  At AT levels >7x baseline, IIa formation is totally inhibited (data not 
shown).  These results support the concept that the AT regulatory system is expected to 
play a major role in anticoagulation therapy.  
 
Fibrinolytic Simulations -The fibrinolytic  simulations were limited to the following agents: 
Pg, mPG, P, tPA, fibrin, PAI, AP, TAFI, II, and TM.  Plasminogen activation by tPA is 
stimulated by fibrin and augmented by plasmin catalyzed feedback modification of fibrin.  
A modified version of plasminogen designed to simulate the Glu1 and Lys78 form of 
plasminogen (mPG) was utilized.  mPG does not generate plasmin thereby attenuating 
the self-activating positive feedback associated with plasmin.  In order to investigate the 
rate of plasminogen activation, the concentration of the mPG is plotted against time 
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under various conditions (Fig 7).  The control group has neither aTAFI nor PG.  
Therefore, the rate of mPG activation is solely related to tPA concentration.  The group  
associated with P.  At early time points, mPG consumption is equivalent among all the 
groups.  Later on, when native P is present, the rate of mPG consumption is 
 
 
 
 
 
 
 
 
 
 
 
 
with PG and no ATAFI evaluate the positive feedback associated with P.  The ATAFI 
groups investigate the effects of ATAFI on the suppression of the positive feedback is  
accelerated.  This effect is attenuated by aTAFI and is eliminated at aTAFI 
concentrations of 5nM resulting in a curve virtually indistinguishable from the control. 
 
Antiplasmin inhibits fibrinolysis by rapidly forming a reversible bond with plasmin.  In 
order to investigate the kinetics associated with AP, the unbound P concentration was 
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Figure 6: Figure 4:  Total thrombin generation profile with 130pM TF-VIIa with AT & TFPI.  A) thrombin 
generation profile with 130pM TF-VIIa at various levels of TFPI.  Circle = ½ baseline concentration, + = baseline, 
large plus = 2x baseline, X = 4x baseline, x = 6x baseline, square = 10x baseline, and x = 20x baseline B) thrombin 
generation profile with 130pM TF-VIIa at various levels of AT.  circle = ½ baseline concentration, triangle = baseline, 
plus = 2x baseline, X = 3x baseline Insert: thrombin generation profile with 130pM TF-VIIa at 4x AT (circle) and 6x AT 
(squares).  N=10. 
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plotted against time with AP and P present in equimolar concentrations.  Figure 8 shows 
the majority of P is bound within 5 seconds.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Effect of aTAFI on the activation of plasminogen.  The concentration of uncleaved modified 
plasminogen is plotted against time.  Fibrinogen was present in 3µM and 200nM modified plasminogen. The 
reactions were initiated by 5nM tPA.  Controls (circle) lacked P and aTAFI.  P 5nM and aTAFI (square = 0nM, 
triangle = 1nM and plus = 5nM) were present in the experimental groups.     The control and 5nM aTAFI groups 
overlap and cannot be distinguished.  N=5. 
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PAI inhibits tPA by reversibly binding tPA.  The rate of PG activation by tPA was used to 
determine the effectiveness of PAI.  Following two minutes of equilibration of various 
tPA concentrations +/- PAI with fibrin, PG was added (Figure 9).  The rate of initial PG 
activation was plotted vs. time.  The presence of a constant amount of PAI induces the 
formation of tPA-PAI complexes and a concomitant decrease in the amount of tPA that 
can bind to fibrin.  As a result of this relative decrease in tPA concentration, the rate of 
plasminogen activation is decreased. 
 
Figure 10 demonstrates the kinetics of TAFI activation by IIa-TM.  TM concentration 
was varied over different concentrations of TAFI in the presence of IIa (1nm) .  The 
initial rate of TAFI activation was plotted vs. time.  The rate of TAFI activation is 
significantly increased in the presence of TM. 
 
Figure 8: Plasmin-Antiplasmin binding kinetics.  Equimolar concentrations (1000nM) of Plasmin and 
Antiplasmin were combined.  Unbound Plasmin concentration is plotted over time.  N=5. 
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Figure 9: Effect of PAI on the rate of plasminogen activation by tPA.  The rate of activation of plasminogen 
was plotted vs. tPA concentration.  Various concentrations of tPA (5, 10, 15, 20, 25, 38, 50, 100,  and 150 IU/mL) 
were combined with 200nM plasminogen and 3µM fibrin in the absence (open circles) and presence of 20 IU/mL 
PAI (closed circles).   In the presence of PAI, the velocity curve is shifted to the right indicating delayed 
plasminogen activation.  N=5. 
 
Figure 10: Thrombomodulin concentration dependence of initial rates of TAFI activation.  The thrombin 
concentration is 1 nM.  The TM concentration was varied from 1nM, 6 nM to 50nM.  The TAFI concentration was 
varied from 0.26 (circles), 0.52 (square), 1 (triangle), to 2 (plus) µM (from bottom to top).  TM increases the 
catalytic efficiency of TAFI activation by IIa.  N=5. 
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To determine the effects of aTAFI on tPA mediated fibrinolysis, lysis assays were 
performed on a system of purified fibrinolytic components in the presence and absence 
of 63 nM aTAFI.  The system was composed of: fibrinogen (3 uM), tPA, (5nM) and  
plasminogen (5nM).  Lysis times were defined as the time required to lyse half of the 
fibrin.  The lysis times were 33m +/- in the absence of aTAFI and 70m +/-  in the 
presence of aTAFI.  
 
Simulation of Common Coagulation Tests- The results described above of ABMS in 
simulating the extrinsic pathway indicated that it might be possible to reliably simulate 
the entire clotting cascade. Two in vitro tests, the prothrombin time (PT) and the 
activated partial thromboplastin time (aPTT), are commonly utilized in assessing the 
coagulation status of patients. Depending on the initiator, either TF (PT) or kaolin 
(aPTT), the test probes the fidelity of the extrinsic or the intrinsic pathway as a part of 
the whole cascade.  As these test are performed on human plasma , except for the 
bolus of the initiator, all factors of the clotting cascade are typically present at their 
normal plasma levels (Appendix 3). In order to simulate plasma, the full CF system 
(utilizing all 106 rules and 57 agent types) was included in the simulations using the 
normal mean concentration for the factors.  In order to initiate coagulation in the PT 
assay, excess TF (100,000 agents) was introduced.  This TF concentration is 100x that 
of VII; therefore the initial reaction is driven by VII concentrations.  Figure 11 shows the 
formation of clot in the PT assay. In a manner similar to plasma PT, the ABMS displays 
initiation, propagation and termination of the coagulation signal.  A median clotting time 
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of 13.7s +/- 1.2 (normal in vitro PT is between 12-15s).  These results suggest that the 
clinically utilized PT assay can be readily simulated using ABMS.   
 
Similarly, the fidelity of the intrinsic pathway was tested by performing aPTT 
simulations.  In order to initiate coagulation, the intrinsic pathway is activated by using 
excess kaolin (100,000 agents) to activate factor XII.  The results were found to be 
similar to the PT assay with the exception of a longer initiation phase (Fig 11); the final 
clot level and the rate of clot formation were identical to the simulated PT assay.   A 
median clotting time of 29.7s +/- 2.0 s was calculated for the simulated aPTT test, which 
compares favorably with the normal in vitro aPTT of 24-40s.  Thus, all the parameters 
characteristic of both the PT and aPTT assays, including the clot time, rate and level of 
clot formation, support the conclusion that ABMS can reliably model the entire blood 
coagulation cascade. 
 
Simulation of Clinical Pathologies - The next step in analyzing the behavior of the ABMS 
is simulating clinical pathologies.  In the first scenario, we simulated hemophilia B 
(Christmas disease).  Hemophilia B is a disease in which patients have an increase in 
their aPTT times, spontaneous hemorrhages, and difficulty clotting after minor injuries 
due to abnormal levels of Factor IX.  In order to simulate Hemophilia B, the system was 
perturbed by examining the effects of decreased concentration of Factor IX on the aPTT  
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assay described in the previous section.  In this case, the full CF system was included 
in the simulations using the normal mean concentration for the factors with the 
exception of Factor IX.  The clinical assay used to monitor Hemophilia B is the aPTT.  
The aPTT times of Hemophilia B patients was simulated by decreasing the initial Factor 
IX concentrations otherwise using the full system as described above (Figure 12a).  Mild 
hemophilia is defined as Factor IX activity 10-40% of normal with resultant aPTT times 
that are normal or only slightly increased.  Figure 12a demonstrates the range of aPTT 
to be between 30-40 s.  Moderate hemophilia is defined as factor IX activity between 1 
and 10%.  Using 2% of normal Factor IX levels gives aPTT times equal to 101.9s +/- 
23.88.  Severe hemophilia is defined as Factor IX levels < 1%.  At this Factor IX 
concentration, clot formation was totally inhibited and the aPTT times were greater than 
Figure 11: Figure 9: Clot as a function of time when measuring the PT (circles) and aPTT (plus) of normal 
plasma.  The initiation, propagation and termination of clot formation are demonstrated. aPTT times are ~2x 
longer than PT times due to longer initiation phase.  N=10. 
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160s as the simulations were terminated.  These aPTT times are an accurate reflection 
of  those seen clinically in Hemophilia B patients. 
 
Another interesting clinical condition is one in which AT binding to heparin is impaired.  
Despite normal plasma AT levels, impaired AT-H binding is associated with a 
hypercoagable state characterized by an increased risk of thromboembolic disease as 
well as intrauterine fetal demise (IUFD)19-23.  This condition was simulated by changing 
the joining parameter that determined whether AT and H react when they collide 
(increasing it to 10x baseline to decreasing it to 1/1000 baseline).  A concentration of 
heparin (H8000) that leads to impaired clotting was used to demonstrate the effect of 
the change in AT-H binding.  The clinical test used to measure the effects of heparin is 
the aPTT.  Figure 12b demonstrates the effects of changing the AT-H binding 
probability from 10x baseline to 1/1000 baseline.  The aPTT time decreased from > 
160s, in the case of 10x baseline, to clotting times that are the equivalent of blood with 
no heparin, in the cases of 1/100 baseline and 1/1000 baseline binding probability.  The 
results demonstrate that decreasing the AT-H binding probabilities leads to a 
hypercoagulable state. 
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Pharmacologic Simulations - Pharmaceutical agents, e.g., heparin and warfarin, are 
routinely used to modulate the coagulation state of patients. To test whether the effect 
of these agents can be incorporated in the coagulation model, simulations were 
performed in the presence of heparin and warfarin.  These results show that drugs such 
as heparin, warfarin, activated protein C, etc… can easily be simulated using the model.  
Figure 13a demonstrates the effects of therapeutic and supra-therapeutic heparin on 
the aPTT times.  Heparin is a commonly used inpatient drug given via IV for anti-
coagulating patients for DVT, PE, and MI.  Heparin serves to activate AT thereby 
increasing the reaction rate a thousand-fold.  As heparin concentration increases from 
3000 Units to 11,000 Units so do the aPTT times from ~30s to the maximum of 160s in 
a non-linear manner.  As is well known to clinicians, the simulations demonstrate that 
the change in concentration from therapeutic levels (8000U) to super-anticoagulated 
levels (11,000 Units) is very small, and can make heparin titrations problematic. 
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Figure 12: aPTT times under pathophysiologic conditions.  A) Hemophilia B-  As factor IX concentration 
decreases aPTT times increase until clotting is totally inhibited in severe hemophilia (<1% baseline IX 
concentrations)  B) AT-H binding deficiency-  Impaired binding of heparin to AT returns aPTT times to baseline.  
Increasing binding probabilities lead to total inhibition of clotting.  N=10. 
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Similarly, Figure 13b demonstrates the effects of therapeutic and supra-therapeutic 
levels of the medication warfarin.  Warfarin is a common medication used in the 
outpatient setting, given by mouth, to patients that require long term anti-coagulation.  .  
Warfarin inhibits the vitamin K-dependent formation of fully functional coagulation 
factors.  The clinical test used to monitor the effects of warfarin is the PT time.  The 
consequences of warfarin administration were simulated by decreasing concentrations 
of vitamin K dependant factors (II, VII, IX, and X) from 90% baseline levels to 1% 
baseline levels.  As expected, decreasing levels of the coagulation factors led to 
increasing PT times in a non-linear manner until the maximum of 150s is reached. 
 
Discussion: 
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Figure 13: Effects of pharmacologic agents on coagulation assays. A) Heparin – As heparin 
concentrations increase, so do aPTT times.   B) Coumadin – As Vitamin K dependant factors decrease, 
PT times increase.  N=10. 
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The initial results of this paper indicate that the in vitro CF system can be readily 
simulated using ABMS.  The model used in this paper successfully simulated aPTT and 
PT times at normal physiologic conditions, abnormal physiologic conditions (hemophilia 
B and AT-H binding defect), and after pharmaceutical interventions (warfarin and 
heparin).  Furthermore, the emergence of a threshold for the generation of thrombin 
was conclusively demonstrated.  The non-linearities of the CF system were captured 
using this ABMS.  The ability of ABMS to simulate results that are found in clinical 
studies was demonstrated.  The ability to predict clinical trials would be an invaluable 
tool for clinical research.  The ability to vary initial concentrations of CF factors that 
mimics what would be seen in a normal population combined with the error bars 
associated with the data are unique to ABMS and provide the ability to simulate in vitro 
experiments and clinical trials. 
 
The CF systems interact strongly at the molecular and cellular level; they thereby 
operating as a coherently linked system, to generate several pathological and 
physiological responses. The highly complex CF system presents a challenging 
problem of identifying the root cause of many known coagulation defects. To date the 
contribution of each system as a part of the network has not been attempted. We have 
developed an ABMS of the CF cascade that allows systematic evaluation of each of its 
components – individually and as a complex entity.  The model allows a comprehensive 
analysis of the CF cascade that provides insight into understanding and predicting the 
pathophysiologic responses arising from variations in molecular and cellular 
components. 
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Computational systems biology is a rapidly growing field that provides tools to analyze 
and understand dynamic evolutionary networks such as the one presented by CF9-11. A 
major advantage of this approach is its rapid, real time analysis of multiple biological 
systems, each of which can be a highly coordinated independent network interacting 
with other networks in the group at one or more branch points. These independent 
networks can be thought of as small molecular machines, which work co-operatively to 
form a large, multi-component molecular machine producing one or more physiological 
responses. Understanding the mechanism and co-operativity of these networks as well 
as predicting the physiological response to appropriate pharmaceutical agents is an 
extremely difficult and intricate task. Advanced systems biology techniques, e.g., 
computational technology, hold major promise in achieving this goal and consequently 
may be extremely useful in understanding patho-physiological conditions and their 
treatment.   
 
ABMS allows a real time analysis of the coagulation system that is difficult if not 
impossible to obtain through in vivo experiments.  Additionally, ABMS provides an 
opportunity to understand the complex interplay among the various subsystems at any 
point in time.  Reductionist in vitro experimental techniques have allowed a detailed 
understanding of the individual chemical reactions involved in the process of 
coagulation.  ABMS represents a non-reductionist approach of studying the biologic 
process as a whole, while retaining the information at an individual level.  The 
information obtained by studying the individual reactions is used as the basis for the 
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rules governing the updating of the ABMS. The advantages of ABMS include the ability 
to simulate the non-linear aspects of the coagulation system.  As the agents are able to 
change state based on their environment, the model adapts and accounts for changes 
such as dearth/excess of coagulation inhibitors, absence of factors, or therapeutic 
interventions.  The time required to update the model is one disadvantage of ABMS as it 
is computationally expensive for large systems with many elements; however a specific 
advantage of this model is its ability to allow for the addition of newly discovered 
mediators, which can impact upon both coagulation and inflammation. More importantly, 
the model has a high probability of exhibiting emergence in which its outputs produce 
unanticipated results, which can then be biologically confirmed. Such properties are 
particularly useful in the discovery of diagnostic and therapeutic interventions. 
Comprehensive modeling of the traditional coagulation cascade allows virtual 
experimentation of the effects of local and systemic injury on coagulation.  
 
Only by creating models, which account for these seemingly diverse but clearly 
connected processes can one hope to improve our overall understanding of the 
coagulation process and to create more powerful diagnostic and therapeutic options.  
We have employed an ABMS in our current approach due to the potential ability to 
quantitatively analyze individual components of each system at every point of 
simulation.  ABMS is a dynamic modeling and simulation tool that allows the study of 
dynamic non-linear networked systems.  ABMS represents a non-reductionist approach 
of studying the biologic process as a whole, while retaining the information at an 
individual level.  The complexity of the system has stymied experimental efforts to gain 
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a system level understanding of the coagulation cascade and its subnetwork 
components.  ABMS may readily provide elucidation of the pathophysiology of diseases 
related to the coagulation system.  The model may also provide insight into individual 
disease processes such as genetic and acquired disorders of coagulation.   
 
A major advantage with ABMS is the ability to monitor each coagulation factor as 
„clotting‟ proceeds.  This implies that the effect of a large number of factors that 
influence coagulation (e.g. natural and pharmaceutical anticoagulants, natural and 
pharmaceutical fibrinolytic agents, and intrinsic and external inflammation mediators) 
can be simulated readily.  These ABMS are expected to provide information on the 
overall progress of clotting as well as on individual coagulation factor as a function of 
time. Thus, ABMS of the coagulation cascade affords the ability to simulate the effect of 
heparins / low molecular weight heparins, coumadins, and factor Xa / thrombin inhibitors 
at a systemic level for the first time. 
 
Computational modeling allows the creation of rapid and inexpensive virtual laboratories 
to generate and test hypotheses13, 14.  More importantly, simulations provide clinical 
tools to design and test novel therapeutic strategies, while affording opportunities to 
predict adverse events during drug development.  Additionally, bedside simulations will 
allow personalized medicine in that replacement factor concentrations can be calculated 
for individual hemophiliac patients, heparin doses can be titrated, etc…  Additional 
applications of the model include discovery of new mediators, understanding of proximal 
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and distal effects of interactions between systems, discovery of new diagnostic and 
therapeutic options, and development of new software and algorithms for simulation.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
93
  
References 
1. Bajzar L, Morser J, Nesheim M. TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation 
and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex. J Biol Chem 
1996;271:16603-8. 
2. Monroe DM, Hoffman M. What Does It Take to Make the Perfect Clot? Arterioscler Thromb Vasc 
Biol 2006;26:41-8. 
3. Zhu D. Mathematical modeling of blood coagulation cascade: kinetics of intrinsic and extrinsic 
pathways in normal and deficient conditions. Blood Coagul Fibrinolysis 2007;18:637-46. 
4. Hockin MF, Jones KC, Everse SJ, Mann KG. A Model for the Stoichiometric Regulation of Blood 
Coagulation. J Biol Chem 2002;277:18322-33. 
5. Jones KC, Mann KG. A model for the tissue factor pathway to thrombin. II. A mathematical 
simulation. J Biol Chem 1994;269:23367-73. 
6. Bonabeau E. Agent-based modeling: methods and techniques for simulating human systems. 
Proc Natl Acad Sci U S A 2002;99 Suppl 3:7280-7. 
7. An G. Agent-based computer simulation and sirs: building a bridge between basic science and 
clinical trials. Shock 2001;16:266-73. 
8. Bankes SC. Agent-based modeling: A revolution? PNAS 2002;99:7199-200. 
9. Bonabeau E. Agent-based modeling: Methods and techniques for simulating human systems. 
PNAS 2002;99:7280-7. 
10. Rider RE. Aspects of Ulam: From Cardinals to Chaos. Science 1989;246:134-. 
11. Wolfram S. Cellular Automata and Complexity: Collected Papers: Westview Press; 1994. 
12. Wilensky U. NetLogo. Evanston, IL: Center for Connected Learning and Computer-Based 
Modeling, Northwestern University; 1999. 
13. van `t Veer C, Mann KG. Regulation of Tissue Factor Initiated Thrombin Generation by the 
Stoichiometric Inhibitors Tissue Factor Pathway Inhibitor, Antithrombin-III, and Heparin Cofactor-II. J 
Biol Chem 1997;272:4367-77. 
14. van `t Veer C, Golden NJ, Kalafatis M, Mann KG. Inhibitory Mechanism of the Protein C Pathway 
on Tissue Factor-induced Thrombin Generation. SYNERGISTIC EFFECT IN COMBINATION WITH TISSUE 
FACTOR PATHWAY INHIBITOR. J Biol Chem 1997;272:7983-94. 
15. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A Study of the Mechanism of Inhibition of 
Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor. J Biol Chem 1998;273:27176-81. 
16. Christensen U, Bangert K, Thorsen S. Reaction of human alpha2-antiplasmin and plasmin 
stopped-flow fluorescence kinetics. FEBS Lett 1996;387:58-62. 
17. Masson C, Angles-Cano E. Kinetic analysis of the interaction between plasminogen activator 
inhibitor-1 and tissue-type plasminogen activator. Biochem J 1988;256:237-44. 
18. Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood 
coagulation. J Biol Chem 2002;277:18322-33. 
19. O'Ddonnell JS, Hinkson L, McCarthy A, Manning R, Khan A, Laffan MA. Antithrombin Nagasaki 
(Ser 116 to Pro): a rare antithrombin variant with abnormal heparin binding presenting during 
pregnancy. Blood Coagul Fibrinolysis 2006;17:217-20. 
20. Tsiang M, Jain AK, Gibbs CS. Functional Requirements for Inhibition of Thrombin by 
Antithrombin III in the Presence and Absence of Heparin. J Biol Chem 1997;272:12024-9. 
21. Owen MC, Borg JY, Soria C, Soria J, Caen J, Carrell RW. Heparin binding defect in a new 
antithrombin III variant: Rouen, 47 Arg to His. Blood 1987;69:1275-9. 
22. Bauters A, Zawadzki C, Bura A, et al. Homozygous variant of antithrombin with lack of affinity for 
heparin: management of severe thrombotic complications associated with intrauterine fetal demise. 
Blood Coagul Fibrinolysis 1996;7:705-10. 
94
  
23. Dewerchin M, Herault J-P, Wallays G, et al. Life-Threatening Thrombosis in Mice With Targeted 
Arg48-to-Cys Mutation of the Heparin-Binding Domain of Antithrombin. Circ Res 2003;93:1120-6. 
24. O'Brien DP, Kemball-Cook G, Hutchinson AM, et al. Surface plasmon resonance studies of the 
interaction between factor VII and tissue factor. Demonstration of defective tissue factor binding in a 
variant FVII molecule (FVII-R79Q). Biochemistry 1994;33:14162-9. 
25. Krishnaswamy S. The interaction of human factor VIIa with tissue factor. J Biol Chem 
1992;267:23696-706. 
26. Shobe J, Dickinson CD, Edgington TS, Ruf W. Macromolecular Substrate Affinity for the Tissue 
Factor-Factor VIIa Complex Is Independent of Scissile Bond Docking. J Biol Chem 1999;274:24171-5. 
27. Butenas S, Mann KG. Kinetics of human factor VII activation. Biochemistry 1996;35:1904-10. 
28. Baugh RJ, Broze GJ, Jr., Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by 
tissue factor pathway inhibitor. J Biol Chem 1998;273:4378-86. 
29. Baugh RJ, Dickinson CD, Ruf W, Krishnaswamy S. Exosite interactions determine the affinity of 
factor X for the extrinsic Xase complex. J Biol Chem 2000;275:28826-33. 
30. Baugh RJ, Krishnaswamy S. Role of the activation peptide domain in human factor X activation 
by the extrinsic Xase complex. J Biol Chem 1996;271:16126-34. 
31. Bergum PW, Cruikshank A, Maki SL, Kelly CR, Ruf W, Vlasuk GP. Role of zymogen and activated 
factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex by 
recombinant nematode anticoagulant protein c2. J Biol Chem 2001;276:10063-71. 
32. de Moerloose P, Bounameaux HR, Mannucci PM. Screening test for thrombophilic patients: 
which tests, for which patient, by whom, when, and why? Semin Thromb Hemost 1998;24:321-7. 
33. Bom VJ, van Hinsbergh VW, Reinalda-Poot HH, Mohanlal RW, Bertina RM. Extrinsic activation of 
human coagulation factors IX and X on the endothelial surface. Thromb Haemost 1991;66:283-91. 
34. Tankersley DL, Finlayson JS. Kinetics of activation and autoactivation of human factor XII. 
Biochemistry 1984;23:273-9. 
35. Gailani D, Broze GJ, Jr. Factor XI activation in a revised model of blood coagulation. Science 
1991;253:909-12. 
36. Rawala-Sheikh R, Ahmad SS, Ashby B, Walsh PN. Kinetics of coagulation factor X activation by 
platelet-bound factor IXa. Biochemistry 1990;29:2606-11. 
37. Lollar P, Parker ET, Fay PJ. Coagulant properties of hybrid human/porcine factor VIII molecules. J 
Biol Chem 1992;267:23652-7. 
38. Fay PJ, Smudzin TM. Characterization of the interaction between the A2 subunit and A1/A3-C1-
C2 dimer in human factor VIIIa. J Biol Chem 1992;267:13246-50. 
39. Fay PJ, Beattie TL, Regan LM, O'Brien LM, Kaufman RJ. Model for the factor VIIIa-dependent 
decay of the intrinsic factor Xase. Role of subunit dissociation and factor IXa-catalyzed proteolysis. J Biol 
Chem 1996;271:6027-32. 
40. Lawson JH, Butenas S, Ribarik N, Mann KG. Complex-dependent inhibition of factor VIIa by 
antithrombin III and heparin. J Biol Chem 1993;268:767-70. 
41. Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC. The role of phospholipids and 
factor Va in the prothrombinase complex. J Biol Chem 1980;255:274-83. 
42. Higgins DL, Lewis SD, Shafer JA. Steady state kinetic parameters for the thrombin-catalyzed 
conversion of human fibrinogen to fibrin. J Biol Chem 1983;258:9276-82. 
43. Monkovic DD, Tracy PB. Activation of human factor V by factor Xa and thrombin. Biochemistry 
1990;29:1118-28. 
44. Hill-Eubanks DC, Lollar P. von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of 
the factor VIII light chain. J Biol Chem 1990;265:17854-8. 
95
  
45. Jesty J, Wun TC, Lorenz A. Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa 
complex by the tissue factor pathway inhibitor in the presence and absence of heparin. Biochemistry 
1994;33:12686-94. 
46. Chuang YJ, Swanson R, Raja SM, Olson ST. Heparin enhances the specificity of antithrombin for 
thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite 
determinant of factor Xa specificity in heparin-activated antithrombin. J Biol Chem 2001;276:14961-71. 
47. Jordan RE, Oosta GM, Gardner WT, Rosenberg RD. The kinetics of hemostatic enzyme-
antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 
1980;255:10081-90. 
48. Schoen P, Lindhout T. The in situ inhibition of prothrombinase-formed human alpha-thrombin 
and meizothrombin(des F1) by antithrombin III and heparin. J Biol Chem 1987;262:11268-74. 
49. Pixley RA, Schapira M, Colman RW. The regulation of human factor XIIa by plasma proteinase 
inhibitors. J Biol Chem 1985;260:1723-9. 
50. Olson ST, Sheffer R, Francis AM. High molecular weight kininogen potentiates the heparin-
accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of 
kallikrein. Biochemistry 1993;32:12136-47. 
51. Olson S, Srinivasan K, Bjork I, Shore J. Binding of high affinity heparin to antithrombin III. 
Stopped flow kinetic studies of the binding interaction. J Biol Chem 1981;256:11073-9. 
52. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 
2005;129:307-21. 
53. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 
1991;78:3114-24. 
54. Bajzar L. Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway. Arterioscler 
Thromb Vasc Biol 2000;20:2511-8. 
55. Guimaraes AH, Rijken DC. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in 
a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an 
internal clot lysis model. Thromb Haemost 2004;91:473-9. 
56. Walker JB, Bajzar L. The Intrinsic Threshold of the Fibrinolytic System Is Modulated by Basic 
Carboxypeptidases, but the Magnitude of the Antifibrinolytic Effect of Activated Thrombin-activable 
Fibrinolysis Inhibitor Is Masked by Its Instability. J Biol Chem 2004;279:27896-904. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
96
  
Appendix 1: 
 
Entity Description 
XI Factor XI Activates XII and IX 
XIa Activated factor XI 
XII Factor XII (Hagemon factor).  Activates XI. 
XIIa Activated factor XII 
XIII Factor XIII.  Crosslinks fibrin polymers to form mature clot. 
XIIIa Activated factor XIII 
IX Factor IX (Christmas factor) Activates X.  Forms tenase complex  
Ixa Activated factor IX 
VIII Factor VIII.  Co-factor of IX – Forms tenase complex  
VIIIa Activated factor VIII 
VIIIa1 Factor VIIIa spontaneously dissociates into inactive VIIIa1 + VIIIa2 
VIIIa2 Factor VIIIa spontaneously dissociates into inactive VIIIa1 + VIIIa2 
IXa-VIIIa tenase complex - activates X 
IXa-VIIIa-X IXa-VIIIa-X complex 
VII Factor VII.  Activates IX and X. 
VIIa Activated factor VII 
II Factor II (prothrombin).  Activates F, V, VII, XIII 
Iia Activated factor II 
X Factor X.  Activates II.  Co-factor of V – forms prothrombinase complex 
Xa Activated factor X 
V Factor V.  Co-factor of X – forms prothrombinase complex  
Va Activated V 
Va-Xa prothrombinase complex – activates II 
TF Tissue Factor.  Activates X in combination with VIIa 
TF-VIIa TF-VIIa complex 
F Fibrinogen – (Factor I) forms clot after conversion to fibrin and polymerization 
Fm Fibrin monomer – forms clot after spontaneous polymerization  
HMWK high molecular weight kininogen – co-factor for activation of XI, XII, and PK 
XI Factor XI 
XIa Activated Factor XI 
XII Factor XII 
XIIa Activated Factor XII 
PK Prekallikrein 
K Kallikrein 
AT Antithrombin III – inhibits TF-VIIa, IIa, IXa, XIa, XIIa and Xa 
AT-Xa AT-Xa complex 
AT-IXa AT-IXa complex 
AT-IIa AT-IIa complex 
AT-TF-VIIa AT-TF-VIIa complex 
AT-XIa AT-XIa complex 
AT-XIIa AT-XIIa complex 
AT-K AT-K complex 
H Heparin - co-factor of AT  
AT-H Antithrombin III - Heparin Complex 
PC Protein C 
aPC Activated PC.  Inhibits VIIa 
Ka Kaolin - activates the contact portion of the intrinsic system 
TFPI Tissue Factor Pathway Inhibitor  - inhibits VIIa-TF, Xa 
TFPI-Xa TFPI-Xa complex 
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TF-VIIa-Xa-TFPI TF-VIIa-Xa-TFPI complex 
PG Plasminogen 
tPA Tissue Plasminogen Activator. Converts PG to P. 
PAI Plasminogen Activator Inhibitor.  Inhibits tPA. 
tPA-PAI tPA-PAI complex 
P Plasmin.  Degrades fibrin. 
AP Anti-Plasmin.  Inhibits P. 
P-AP Plasmin - Anti-Plasmin complex 
TAFI Thrombin Activatable Fibrinolysis Inhibitor- Prevents the P mediated increased rate of 
PG activation. 
aTAFI Activated TAFI 
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Appendix 2: 
 
# Reaction Pathway 
1 VII + TF  VII-TF4, 24, 25 Extrinsic 
2 VII + TF  VII-TF4, 24, 25 Extrinsic 
3 VIIa + TF  VIIa-TF4, 24, 26 Extrinsic 
4 VIIa + TF VIIa-TF4, 24, 26 Extrinsic 
5 VIIa-TF + VII  VIIa-TF + VIIa3, 4, 27 Extrinsic 
6 Xa + VII  Xa + VIIa3, 4, 27 Extrinsic 
7 IIa + VII  IIa + VIIa3, 4, 27 Extrinsic 
8 VIIa-TF + X  VIIa-TF-X4, 26, 28 Extrinsic 
9 VIIa-TF + X  VIIa-TF-X4, 26, 28 Extrinsic 
10 VIIa-TF-X  VIIa-TF + Xa4, 29, 30 Extrinsic 
11 VIIa-TF + Xa  VIIa-TF-Xa4, 30, 31 Extrinsic 
12 VIIa-TF + Xa  VIIa-TF-Xa4 Extrinsic 
13 VIIa-TF + IX  VIIa-TF-IX4, 32, 33 Extrinsic 
14 VIIa-TF + IX  VIIa-TF-IX4, 32, 33 Extrinsic 
15 VIIa-TF-IX  VIIa-TF + IXa4, 32, 33 Extrinsic 
16 XII + Surface + HMWK  XIIa + Surface + HMWK Intrinsic 
17 XII +  XIIa   XIIa  + XIIa3, 34 Intrinsic 
18 PK+ XIIa + HMWK  K +  XIIa + HMWK3, 34 Intrinsic 
19 XII + K + HMWK  XIIa + K+ HMWK3, 34 Intrinsic 
20 XI + XIIa + HMWK XIa + XIIa +HMWK3, 35 Intrinsic 
21 XII +  XIa   XIIa  + XIa3 Intrinsic 
22 IX + XIa  IXa + XIa3 Intrinsic 
23 X + IXa  Xa + IXa3 Intrinsic 
24 XI + IIa  XIa + IIa3 Intrinsic 
25 VIIIa + IXa   VIIIa-IXa4, 32 Intrinsic 
26 VIIIa + IXa   VIIIa-IXa4, 32 Intrinsic 
27 VIIIa-IXa + X   VIIIa-IXa-X4, 32, 36 Intrinsic 
28 VIIIa-IXa + X   VIIIa-IXa-X4, 32, 36 Intrinsic 
29 VIIIa-IXa-X   VIIIa-IXa-Xa4, 32, 36 Intrinsic 
30 VIIIa  VIIIa1 +  VIIIa24, 37 Intrinsic 
31 VIIIa  VIIIa1 +  VIIIa24, 37, 38 Intrinsic 
32 VIIIa-IXa   VIIIa1 +  VIIIa2 + IXa4, 39 Intrinsic 
33 Xa + II  Xa + IIa3, 4, 40, 41 Common 
34 IIa + VIII  IIa + VIIIa3, 4, 28 Common 
35 F + IIa  Fm + IIa3, 42 Common 
36 IIa + V  IIa + Va3, 4, 32, 43, 44 Common 
37 Xa + Va  Xa-Va4, 32 Common 
38 Xa + Va  Xa-Va4, 32 Common 
39 Xa-Va + II   Xa-Va-II4, 32 Common 
40 Xa-Va + II   Xa-Va-II4, 32 Common 
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41 Xa-Va-II   Xa-Va + IIa4, 32 Common 
42 XIII + IIa  XIIIa + IIa3 Common 
43 Xa + TFPI  Xa-TFPI4, 28, 45 TFPI 
44 Xa + TFPI Xa-TFPI4, 28, 45 TFPI 
45 TF-VIIa-Xa + TFPI   TF-VIIa-Xa-TFPI4, 28 TFPI 
46 TF-VIIa-Xa + TFPI   TF-VIIa-Xa-TFPI4, 28 TFPI 
47 TF-VIIa + Xa-TFPI   TF-VIIa-Xa-TFPI4, 28 TFPI 
48 AT + Xa  AT-Xa3, 4, 46 AT-H 
49 AT +  TF-VIIa   AT-TF-VIIa 3, 4, 40  AT-H 
50 AT + IXa  AT-IXa 3, 4, 46, 47 AT-H 
51 AT + IIa  AT-IIa 3, 4, 48 AT-H 
52 AT +  XIa   AT-XIa3   AT-H 
53 AT +  XIIa   AT-XIIa3, 49   AT-H 
54 AT +  K   AT-K3, 50   AT-H 
55 AT + H  AT-H51 AT-H 
56 AT + H  AT-H51 AT-H 
57 AT-H + Xa  AT-Xa + H46 AT-H 
58 AT-H +  TF-VIIa   AT-TF-VIIa + H40 AT-H 
59 AT-H + IXa  AT-IXa + H46, 47   AT-H 
60 AT-H + IIa  AT-IIa + H48   AT-H 
61 AT-H  +  XI   AT-XI + H   AT-H 
62 AT-H  +  XII   AT-XII + H49   AT-H 
63 AT-H  +  K   AT-K + H50  AT-H 
64 PC + IIa  aPC + IIa14 APC 
65 IIa + TM  IIa-TM14 APC 
66 IIa + TM IIa-TM APC 
67 PC + IIa-TM  aPC + IIa-TM14 APC 
68 aPC +Va  aPC + Vi
14 APC 
69 PG + tPA  P +  tPA1, 17, 52, 53 Fibrinolysis 
70 mPG + tPA  tPA1, 17, 52, 53 Fibrinolysis 
71 tPA + Fm  tPA-Fm
1, 17, 52, 53  Fibrinolysis 
72 tPA + Fm  tPA-Fm
1, 17, 52, 53 Fibrinolysis 
73 tPA-Fm + PG   tPA-Fm-PG
1, 17, 52, 53 Fibrinolysis 
74 tPA-Fm + PG   tPA-Fm-PG
1, 17, 52, 53 Fibrinolysis 
75 tPA-Fm-PG   tPA-Fm + P
1, 17, 52, 53 Fibrinolysis 
76 P + Fm  P
1, 17, 52, 53 Fibrinolysis 
77 tPA + PAI  tPA-PAI17 PAI 
78 tPA + PAI  tPA-PAI17 PAI 
79 P + AP  AP-P‟16 AP 
80 P + AP  AP-P‟16 AP 
81 AP-P‟  AP-P16 AP 
82 AP-P‟  AP-P16 AP 
83 aTAFI  + Fm  aTAFI-Fm
1, 15, 54-56 TAFI 
84 aTAFI  TAFIi
1, 15, 54-56 TAFI 
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85 IIa+ TAFI  IIa-TAFI1, 15, 54-56 TAFI 
86 IIa+ TAFI IIa-TAFI1, 15, 54-56 TAFI 
87 IIa-TM + TAFI  IIa-TM-TAFI1, 15, 54-56 TAFI 
88 Ia-TM + TAFI  IIa-TM-TAFI1, 15, 54-56 TAFI 
89 IIa-TM-TAFI   II-TM + aTAFI1, 15, 54-56 TAFI 
90 IIa-TAFI  IIa + aTAFI1, 15, 54-56 TAFI 
91 IIa-TAFI + TM  IIa-TAFI-TM1, 15, 54-56 TAFI 
92 IIa-TAFI-TM  IIa-TM + TAFI1, 15, 54-56 TAFI 
93 IIa-TAFI-TM  IIa-TAFI + TM1, 15, 54-56 TAFI 
94 aTAFI  + Fm  aTAFI-Fm
1, 15, 54-56 TAFI 
95 aTAFI-Fm  aTAFI-Fm + Lysine
1, 15, 54-56 TAFI 
96 aTAFI  TAFIi
1, 15, 54-56 TAFI 
97 IIa+ TAFI  IIa-TAFI1, 15, 54-56 TAFI 
98 IIa+ TAFI IIa-TAFI1, 15, 54-56 TAFI 
99 IIa-TM + TAFI  IIa-TM-TAFI1, 15, 54-56 TAFI 
100 Ia-TM + TAFI  IIa-TM-TAFI1, 15, 54-56 TAFI 
101 IIa-TM-TAFI   II-TM + aTAFI1, 15, 54-56 TAFI 
102 IIa-TAFI  IIa + aTAFI1, 15, 54-56 TAFI 
103 IIa-TAFI + TM  IIa-TAFI-TM1, 15, 54-56 TAFI 
104 IIa-TAFI-TM  IIa-TM + TAFI1, 15, 54-56 TAFI 
105 IIa-TAFI-TM  IIa-TAFI + TM1, 15, 54-56 TAFI 
106 IIa-TAFI-TM  IIa-TM + aTAFI1, 15, 54-56 TAFI 
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Appendix 3: 
 
Agent 
Initial  
Concentration 
(microM) 
# of 
Agents 
I 8.83 883,000 
II 1.4 140,000 
V 0.02 2,000 
VII 0.01 1,000 
VIIa 0.0001 10 
VIII 0.0003 30 
IX 0.09 9,000 
X 0.17 17,000 
XI 0.025 2,500 
XII 0.3 30,000 
HMWK 0.9 90,000 
PK 0.58 58,000 
AT 3.4 340,000 
TFPI 0.0025 250 
Protein C 0.065 6,500 
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Abstract 
The coagulation system (CS) is a complex, inter-connected biological system with major physiological 
and pathological roles. The CS may be viewed as a complex adaptive system,
 
in which individual 
components are linked through multiple feedback and feedforward loops.  The non-linear relationships 
between the numerous coagulation factors and the interplay among the elements of the CS render the 
study of this biology at a molecular and cellular level nearly impossible.  We present an Agent Based 
Modeling and Simulation (ABMS) approach for simulating these complex interactions. Our ABMS 
approach utilizes a subset of 52 rules to define the interactions among 33 enzymes and factors of the CS.  
These rules simulate the interaction of each “agent”, such as substrates, enzymes, and cofactors, on a 
two-dimensional grid of ~12,000 cells and ~300,000 agents.  Our ABMS method successfully 
reproduces the initiation, propagation, and termination of thrombin formation due to the activation of the 
extrinsic pathway.  Furthermore, the ABMS is able to demonstrate the emergence of a threshold effect 
for thrombin generation as a result of the synergistic effect of combining anticoagulant systems.   
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Introduction 
 
 
 
 
 
 
 
Coagulation System In the event of an injury to the endothelium, the coagulation system balances the 
need for localized clot formation against prevention of systemic activation.  This finely tuned system is 
composed of an assortment of molecular and cellular “agents” (e.g. substrates, enzymes, cofactors, 
inhibitors, platelets, and endothelial cells) all interacting to generate a stable clot in order to rapidly 
obtain hemostasis
1
.  The new cellular model of hemostasis proposes that the classical pathways of 
coagulation, i.e., the intrinsic and extrinsic pathways, mediate on specific cell surfaces in a tightly 
regulated manner
2-4
. In this model, activation of factor VII (extrinsic, Fig. 1) and factor XII (intrinsic, 
Fig. 1) results in the formation of the multi-molecular tenase and prothrombinase complexes, which 
eventually generate thrombin. Thrombin then cleaves fibrinogen to form fibrin monomers, which 
polymerize to form a three-dimensional clot.   
Figure 1: Coagulation Cascade 
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 Clot formation is regulated in vivo through the antithrombin III-heparin complex (AT-H), activated 
protein C (aPC), and tissue factor pathway inhibitor (TFPI) (Fig. 1). These regulating systems limit 
excessive formation of cross-linked fibrin under hemostatic conditions.  The anticoagulation systems are 
regulated independently, but combine to synergistically control thrombin generation. 
 
The CS may be viewed as a complex adaptive system,
 
in which individual components are linked 
through multiple feedback and feedforward loops.  These loops introduce non-linear relationships 
among the components. A static diagram such as the classically portrayed coagulation pathway (Figure 
1) cannot adequately describe this dynamic evolutionary network. More importantly, the effects of 
several disease states on the imbalances in the CS are difficult to understand.  Thus, the influence of 
diseases that favor coagulation (e.g. myocardial infarction, disseminated intravascular coagulation, 
cerebrovascular accidents, and venous thrombosis), or those that impair coagulation (e.g. hemophilias, 
thrombocytopenias, and von Willebrand disease) remain poorly characterized. 
 
Computational Modeling 
Computational systems biology is an emerging field that provides tools to analyze and understand 
complex adaptive systems such as the CS
5,6
. A major advantage of this approach is its rapid, real time 
analysis of multiple biological systems; each may function as a highly coordinated independent network 
interacting with other networks in the group at one or more branch points. These independent networks 
can be thought of as small molecular machines, which work co-operatively to form a large, multi-
component molecular machine producing one or more physiological responses. Understanding the 
mechanism and co-operativity of these networks as well as predicting the physiological response to 
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appropriate pharmaceutical agents is an extremely difficult and intricate task. Yet, advanced systems 
biology techniques, e.g., computational technology, may achieve this goal with consequent major 
applications in understanding patho-physiological conditions and their treatment.   
Table I: Entity Table 
Entity Description 
IX Factor IX (Christmas factor) 
Activates X.  Forms tenase 
complex  
VIII Factor VIII.  Co-factor of IX – 
Forms tenase complex  
VIIIa Activated factor VIII 
VIIIa1 Factor VIIIa spontaneously 
dissociates into inactive VIIIa1 + 
VIIIa2 
VIIIa2 Factor VIIIa spontaneously 
dissociates into inactive VIIIa1 + 
VIIIa2 
IXa-VIIIa tenase complex - activates X 
IXa-VIIIa-X IXa-VIIIa-X complex 
VII Factor VII.  Activates IX and X. 
VIIa Activated factor VII 
II Factor II (prothrombin).  
Activates F, V, VII, XIII 
IIa Activated factor II (thrombin) 
X Factor X.  Activates II.  Co-
factor of V – forms 
prothrombinase complex 
V Factor V.  Co-factor of X – 
forms prothrombinase complex  
Vi Inactivated V 
Va-Xa Prothrombinase complex – 
activates II 
TF Tissue Factor.  Activates X in 
combination with VIIa 
TF-VIIa TF-VIIa complex 
AT Antithrombin III – inhibits TF-
VIIa, IIa, IXa, XIa, XIIa and Xa 
AT-Xa AT-Xa complex 
AT-IXa AT-IXa complex 
AT-IIa AT-IIa complex 
AT-TF-VIIa AT-TF-VIIa complex 
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TFPI Tissue Factor Pathway Inhibitor  
- inhibits VIIa-TF, Xa 
TFPI-Xa TFPI-Xa complex 
TF-VIIa-Xa-
TFPI 
TF-VIIa-Xa-TFPI complex 
PC Protein C – inactivates Va 
aPC Activated Protein C – activated 
Protein C 
aPC-Va aPC-Va complex 
TM Thrombomodulin – In 
combination with IIa, activates 
PC 
IIa-TM IIa-TM complex 
 
 
To date, most computational models of the coagulation system have focused on using ordinary or partial 
differential equations (ODEs and PDEs)
7-9
.  Differential equations describe the change in the states of 
the variables of the system over time and are derived from known or hypothesized kinetics.  ODE 
models can readily simulate coagulation in vitro as it is a relatively homogenous system
10
; however, 
such models face significant limitations when modeling in vivo hemostasis due to complicating factors 
such as non-stationarity, spatial heterogeneity and the effects of blood flow.
 
Therefore, derivation of 
differential equations suitable for in vivo modeling becomes problematic. 
  
In order to address the shortcomings associated with ODE models, we present the application of a 
computational systems biology approach using agent-based modeling and simulation (ABMS) to 
understand the CS and determine the role of coagulation inhibitors in preventing complete activation of 
thrombin.  ABMS provides a powerful alternative to differential equations
11-13
.  ABMS is a relatively 
new modeling paradigm derived from cellular automata (CA)
14,15
.  ABMS has mobile autonomous 
entities (agents) that can move through space.  Each agent is allowed to assume a finite number of states, 
determined by a pre-defined set of rules. Every agent is individually updated at the end of each operating 
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period according to the pre-set rules. The rules are a function of the current state of the agent and the 
state of its neighbors.   
 
Coagulation Model 
Table II: Rule Table 
# Reaction Pathway 
1 VII + TF  VII-TF7,19-21 Extrinsic 
2 VII + TF  VII-TF7,19-21 Extrinsic 
3 VIIa + TF  VIIa-TF7,19-21 Extrinsic 
4 VIIa + TF VIIa-TF7,19-21 Extrinsic 
5 VIIa-TF + VII  VIIa-TF + VIIa7,8,22 Extrinsic 
6 Xa + VII  Xa + VIIa7,8,22 Extrinsic 
7 IIa + VII  IIa + VIIa7,8,22 Extrinsic 
8 VIIa-TF + X  VIIa-TF-X7,21,23 Extrinsic 
9 VIIa-TF + X  VIIa-TF-X7,21,23 Extrinsic 
10 VIIa-TF-X  VIIa-TF + Xa7,24,25 Extrinsic 
11 VIIa-TF + Xa  VIIa-TF-Xa7,25,26 Extrinsic 
12 VIIa-TF + Xa  VIIa-TF-Xa7 Extrinsic 
13 VIIa-TF + IX  VIIa-TF-IX7,27,28 Extrinsic 
14 VIIa-TF + IX  VIIa-TF-IX7,27,28 Extrinsic 
15 VIIa-TF-IX  VIIa-TF + IXa7,27,28 Extrinsic 
23 VIIIa + IXa   VIIIa-IXa7,28 Intrinsic 
25 VIIIa + IXa   VIIIa-IXa7,28 Intrinsic 
26 VIIIa-IXa + X   VIIIa-IXa-X7,28,29 Intrinsic 
27 VIIIa-IXa + X   VIIIa-IXa-X7,28,29 Intrinsic 
28 VIIIa-IXa-X   VIIIa-IXa-Xa7,28,29 Intrinsic 
29 VIIIa  VIIIa1 +  VIIIa27,30 Intrinsic 
30 VIIIa  VIIIa1 +  VIIIa27,30,31 Intrinsic 
31 VIIIa-IXa   VIIIa1 +  VIIIa2 + IXa7,32 Intrinsic 
32 Xa + II  Xa + IIa7,8,33,34 Common 
33 IIa + VIII  IIa + VIIIa7,8,23 Common 
34 IIa + V  IIa + Va7,8,28,35,36 Common 
35 Xa + Va  Xa-Va7,28 Common 
36 Xa + Va  Xa-Va7,28 Common 
37 Xa-Va + II   Xa-Va-II7,28 Common 
38 Xa-Va + II   Xa-Va-II7,28 Common 
39 Xa-Va-II   Xa-Va + IIa7,28 Common 
40 Xa + TFPI  Xa-TFPI7,23,28 TFPI 
41 Xa + TFPI Xa-TFPI7,23,28 TFPI 
42 TF-VIIa-Xa + TFPI   TF-VIIa-Xa-TFPI7,23,37 TFPI 
108
  
 
 
 
 
 
 
 
 
 
The model described in this paper is designed to simulate thrombin formation in the in vitro 
environment.  Therefore, a limited subset of substrates, reactions, and products from the intrinsic, 
extrinsic, common, AT-H, TFPI, and aPC pathways have been included (Table I & II).  In order to 
create realistic simulations, physiologic concentrations of factors were used in the in silico experiments 
(Table III).  The rates associated with the reactions were taken from the literature and were assumed to 
be performed in saturating phospholipid and calcium conditions.  The simulations were designed to test 
experimental conditions that create thrombin profiles reflective of the threshold phenomena associated 
with physiologic concentrations of coagulation inhibitors.  
 
 
Table III: Baseline plasma concentration of coagulation factors. 
Agent Initial  
Concentration 
(µM) 
# of 
Agents 
TF-VIIa Varies Varies 
II 1.4 280,000 
V 0.02 4,000 
VII 0.01 2,000 
VIIa 0.0001 20 
VIII 0.0003 60 
IX 0.09 18,000 
X 0.17 34,000 
AT 3.4 68,000 
TFPI 0.0025 500 
43 TF-VIIa-Xa + TFPI   TF-VIIa-Xa-TFPI7,23,37 TFPI 
44 TF-VIIa + Xa-TFPI   TF-VIIa-Xa-TFPI7,23,37 TFPI 
45 AT + Xa  AT-Xa7,8,38 AT 
46 AT +  TF-VIIa   AT-TF-VIIa7,8,33 AT 
47 AT + IXa  AT-IXa7,8,38,39 AT 
48 AT + IIa  AT-IIa7,8,40 AT 
49 PC + IIa  aPC + IIa17 aPC 
50 IIa + TM  IIa-TM17 aPC 
51 PC + IIa-TM  aPC + IIa-TM17 aPC 
52 aPC +Va  aPC + Vi 
17
 aPC 
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PC 0.065 13,000 
TM Varies Varies 
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Materials and Methods 
 
Coagulation Model  
The ABMS in this paper uses a two dimensional particle system whereby particles move freely and 
interact on a discrete spatial grid.  In this specific model, we define the particles of the system as the 
reactants, enzymes, and products in the entity table (Table I).  The spatial grid is set as a two 
dimensional grid where the agent‟s location is identified by its x and y coordinates.  Each coordinate 
pair (x, y) delineates a unique location.  The number of grid locations used in these simulations is 
12,321.  The number of agents in the simulations is on the order of 300,000. Each time step of the 
simulation represents 0.01 seconds.   
 
Grid locations in this model are designated as either empty or occupied by one or more substrates, 
enzymes, or reaction products.  The agents are allowed to move freely about the grid.  The movement, 
joining, and breaking are governed by probability rules.  The movement parameter determines the extent 
of each agent‟s motion (0 implies every cell is stationary).  The joining parameter determines the extent 
of interaction between adjacent agents.  The breaking parameter defines the extent of disruption of 
agents that have joined.  This model sets the probability of joining and breaking based on experimentally 
determined kinetic constants.  The movement parameter is set at 1.  The agents are allowed to interact 
with all their neighbors, but meaningful interactions are limited to those in the rule table (Table II).  The 
neighborhood of each agent in this model is defined as all agents located in the same grid location.  
After each time step, the agents move in a random manner to an adjacent grid location.   
 
ABMS modeling requires the assignment of the probability of conversion associated with each chemical 
reaction as defined in the rule table (Table II).  Reductionist in vitro experimental techniques have 
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allowed a detailed understanding of the individual chemical reactions involved in the process of 
coagulation.  The information obtained by studying the individual reactions is used as the basis for the 
rules governing the updating of the ABMS at each time step.  We assigned a probability of conversion 
value related to the kinetics of the reactions.  The initial configuration is random; each substrate and 
enzyme is assigned a predefined number of agents based on their desired initial concentration (Table 
III). 
 
In vivo, prothrombinase and tenase complexes are formed through a combination of three factors. The 
prothrombinase complex is formed by a combination of prothrombin, factor Xa and factor Va; the 
intrinsic tenase complex is formed when factors VIIIa and IXa combine with factor X. These three-body 
complexes are not directly simulated in ABMS, as in vivo, they must arise through sequential 
combination of two molecules. Thus, we utilized a sequential two-body collision approach to generate 
each complex.  
 
The ABMS is designed to represent the in vitro environment.  In this case, the spatial grid is in the shape 
of a rectangle allowing the particles to interact and bounce off the edge of the grid.  There are no 
platelets, RBC, or WBC in the system as in vitro coagulation tests are run on acellular plasma.   
 
Computation  
Netlogo v4.04, a software package designed to run ABMS, was utilized to perform the simulations
16
.  
The user determines the subset of reactants, the subset of reactions, the subset of coagulation factors, 
rate constants, initial factor concentrations, and termination conditions for each simulation.  The 
concentration of every coagulation factor was output every 100 time steps (1 virtual second).  The 
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output of each simulation was stored in a comma separated file.  All simulations were carried out on an 
Intel based desktop personal computer running Microsoft Windows XP.  Up to six simulations were run 
in parallel.  Each simulation ran up to 72 hours depending on the initial and stop conditions.  
Simulations were terminated after 90,000 iterations if the terminating conditions were not met. 
 
Simulations 
Unless otherwise stated, modeling of the system was performed under conditions that simulated 
literature derived mean physiologic concentrations of each soluble factor in normal humans (Table 3).  
The simulations were designed to determine the effects of coagulation inhibitors on thrombin (IIa) 
generation profiles.  Comparisons between the ABMS output and experimental data determined the 
validity of the system.   
 
Results 
   
The threshold dependent formation of IIa in the presence of inhibitors such as AT, PC, and TFPI is an 
important feature of the coagulation system. Figure 2, demonstrates this characteristic profile that results 
as a function of the combination of AT and TFPI.  At low concentrations of TF-VIIa (5pM), the 
threshold value required for production of IIa is not reached; whereas both 30pM and 130pM 
concentration were able to generate a short burst of thrombin.  These results demonstrate the synergistic 
effect of inhibitors (AT and TFPI) on the extrinsic system.  The combination of AT and TFPI results in 
the creation of a threshold concentration of TF-VIIa (between 5pM and 30pM). Below this threshold 
value significant amounts of thrombin are not generated.  
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The combination of PC and TFPI results in the threshold demonstrated in Figure 3.  The experiments 
were initiated by TF-VIIa at 5pM.  With no TM, all of the prothrombin (II)  is converted to thrombin; 
whereas at concentrations of 0.1nM TM  and 10nM TM, generation of thrombin is quenched.  In this  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
case, the threshold is a function of TM concentration.  Thus, a bifurcation point exists between 0nM and 
0.1nM of TM whereby PC in combination with TFPI prevents the burst of thrombin generation. 
 
Figure 4 demonstrates the effects of combining AT and PC.  At concentrations of 5pM of TF-VIIa no 
thrombin was generated (data not shown).  At initial concentrations of 30pM TF-VIIa, the characteristic 
bell shaped curve is observed with no TM and 0.1nM TM.  At 10nM concentrations of TM, the burst of 
thrombin is suppressed. 
 
In figure 5, all three inhibitors are utilized.  No thrombin is generated when initialized with 5pM or  
30pM of TF-VIIa (data not shown).  At 130pM of TF-VIIa, a burst of  thrombin is observed with low  
Figure 2: Thrombin generation as a function of TF-VIIa concentration in the presence of TFPI and AT.  The 
experiments were conducted with 2.5 nM TFPI and 3.4uM AT.  The initiating concentrations of TF-VIIa are 130pm 
(circles), 30pM (triangles), and 5pM (squares).  N=5. 
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TM concentrations (no TM and 0.1nM TM), but is suppressed at 10nM TM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Thrombin generation as a function of TM concentration in the presence of AT and Protein C.  The 
experiments were conducted with 3.4 µM AT and 65 nM Protein C.  The initiating concentration of TF-VIIa is 30nM.  The 
TM concentrations  are 0 (circles),  0.1nM (triangles), and 10nM (squares).  N=5. 
 
 
 
Figure 3: Thrombin generation as a function of TM concentration in the presence of TFPI and Protein C.  
The experiments were conducted with 2.5 nM TFPI and 65 nM Protein C.  The initiating concentration of TF-VIIa is 
5nM.  The TM concentrations  0 (circles), 0.1 nM (triangles), and 10nM (squares).  N=5. 
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Figure 5: Thrombin generation as a function of TM concentration in the presence of TFPI, AT, and Protein C.  The 
experiments were conducted with 2.5 nM TFPI , 3.4 µM AT, and 65 nM Protein C.  The initiating concentration of TF-VIIa 
is 130nM.  The TM are  0 (circles), 0.1 nM (triangles), and 10nM (squares).  N=5. 
 
 
Discussion 
The components of the CS interact strongly at the molecular and cellular level; they thereby operate as a 
coherently linked system that generates both pathological and physiological responses. The highly 
complex CS presents a challenging problem of identifying the root cause of many known coagulation 
defects. To date the contribution of each system as a part of the network has not been attempted. We 
have developed an ABMS of the CS cascade that allows systematic evaluation of each of its components 
– individually and as a complex entity.  The model allows a comprehensive analysis of the CS cascade 
that provides insight into understanding and predicting the pathophysiologic responses arising from 
variations in its molecular and cellular components. 
 
Only by creating models, which account for these seemingly diverse but clearly connected processes can 
one hope to improve our overall understanding of the coagulation process and to create more powerful 
diagnostic and therapeutic options.  We have employed an ABMS in our current approach due to the 
potential ability to quantitatively analyze individual components of each system at every point of 
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simulation.  ABMS is a dynamic modeling and simulation tool that allows the study of dynamic non-
linear networked systems.  ABMS represents a non-reductionist approach of studying the biologic 
process as a whole, while retaining the information at an individual level.  The complexity of the system 
has stymied experimental efforts to gain a system level understanding of the coagulation cascade and its 
subnetwork components.  ABMS may readily provide elucidation of the pathophysiology of diseases 
related to the coagulation system.  The model may prove informative regarding individual disease 
processes such as genetic and acquired disorders of coagulation.   
 
The initial results of this paper indicate that the in vitro coagulation system can be readily simulated 
using ABMS.  Our ABMS approach successfully reproduces the initiation, propagation, and termination 
of thrombin formation in vitro. Furthermore, the ABMS was able to simulate the threshold effect of 
thrombin formation resultant from the synergistic relationship between physiologic concentrations of 
coagulation inhibitors.    This suppression of thrombin is the likely mechanism behind localization of the 
hemostasis response.  The mechanism demonstrated herein provides the rationale for localized 
formation of a blood clot at the site of endothelial injury as opposed to a systemic vascular thrombotic 
response.  Presumably, the thrombin concentrations upstream and downstream of the endothelial injury 
fail to reach self sustaining levels due to the synergistic effects of AT, TFPI, and aPC.  A possible 
therapeutic strategy of manipulating coagulation inhibitors for the treatment of diseases involving the 
systemic activation of the CS, such as trauma induced coagulopathy (TIC), disseminated intravascular 
coagulopathy (DIC), coagulopathy associated with cardiac arrest, etc…, is suggested by the findings in 
this paper. 
 
The next step in the progression of our coagulation model is to simulate the in vivo environment.   
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Expansion of the model will require the addition of blood flow, endothelial cells, white blood cells, 
platelets, and the full complement of coagulation proteins.  Such a model will provide insight into 
complex disease processes that are impossible to obtain using laboratory techniques.  Computational 
systems biology allows the design and implementation of experiments that would be unethical and 
dangerous in the clinical setting; instead, creation of previously unavailable diagnostic and therapeutic 
strategies becomes possible.   
 
ABMS allows a real time analysis of the coagulation system that cannot be obtained through in vivo 
experiments.  Additionally, ABMS provides an opportunity to understand the complex interplay among 
the various subsystems.  The advantages of ABMS include the ability to simulate the non-linear aspects 
of the coagulation system.  Moreover, the model is flexible and able to account for changes such as lack 
of inhibitors, absence of factors, or therapeutic interventions associated with disease processes.  As new 
mediators are discovered they are easily added to the model. 
 
Another major advantage of ABMS is the ability to monitor each coagulation factor as „clotting‟ 
proceeds.  This implies that the effect of a large number of factors that influence coagulation (e.g. 
natural and pharmaceutical anticoagulants, natural and pharmaceutical fibrinolytic agents, and intrinsic 
and external inflammation mediators) can be simulated readily.  These ABMS are expected to provide 
information regarding the overall progress of clotting as well as individual coagulation factors as a 
function of time. Thus, ABMS of the coagulation cascade affords the ability to simulate the effect of 
heparins / low molecular weight heparins, coumadins, and factor Xa / thrombin inhibitors at a systemic 
level for the first time. 
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The last and most important advantage of the model is it is capable of exhibiting emergent behaviors in 
which its outputs produce unanticipated results, which can then be biologically confirmed. Such 
properties are particularly useful in the discovery of diagnostic and therapeutic interventions. 
Comprehensive modeling of the traditional coagulation cascade allows unlimited virtual 
experimentation on the effects of local and systemic injury on coagulation.  
 
The time required to update the model is one disadvantage of ABMS as it is computationally expensive 
for large systems with many elements.  Conversion of the model into other platforms may provide 
significantly decrease the time required to run simulations.   For example, the model can be moved to an 
alternate ABMS platform (I.E. Repast) with an expected halving of the execution time.  Ultimately, 
conversion of the model into a format that can be run on graphical processing units (GPU) may allow 
significant decreases in execution time (on the order of 100x) that could allow simulations to be run at a 
patient‟s bedside in real-time. 
 
Computational modeling allows the creation of rapid and inexpensive virtual laboratories to generate 
and test hypotheses.  More importantly, simulations provide clinical tools to design and test novel 
therapeutic strategies, while affording opportunities to predict adverse events during drug development.  
Additionally, bedside simulations will allow personalized medicine to calculate replacement factor 
concentrations for individual hemophiliac patients, heparin doses can be titrated, etc…  Future 
applications of the model include discovery of new mediators, understanding of proximal and distal 
effects of interactions between systems, discovery of new diagnostic and therapeutic options, and 
development of new software and algorithms for simulation.    
 
 
119
References 
1
 Messmore, HL. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. JAMA 296, 338-, (2006). 
2
 Furie, B & Furie, BC. Mechanisms of Thrombus Formation. N. Engl. J. Med. 359, 938-949, (2008). 
3
 Monroe, DM & Hoffman, M. What Does It Take to Make the Perfect Clot? Arterioscler. Thromb. Vasc. Biol. 26, 41-48, (2006). 
4
 Wagner, DD & Frenette, PS. The vessel wall and its interactions. Blood 111, 5271-5281, (2008). 
5
 An, G. Mathematical modeling in medicine: a means, not an end. Crit Care Med 33, 253-254, (2005). 
6
 Buchman, TG. Nonlinear dynamics, complex systems, and the pathobiology of critical illness. Curr Opin Crit Care 10, 378-382, 
(2004). 
7
 Hockin, MF et al. A Model for the Stoichiometric Regulation of Blood Coagulation. J. Biol. Chem. 277, 18322-18333, (2002). 
8
 Zhu, D. Mathematical modeling of blood coagulation cascade: kinetics of intrinsic and extrinsic pathways in normal and deficient 
conditions. Blood Coagul Fibrinolysis 18, 637-646, (2007). 
9
 Panteleev, MA et al. Mathematical models of blood coagulation and platelet adhesion: clinical applications. Curr Pharm Des 13, 
1457-1467, (2007). 
10
 Jones, KC & Mann, KG. A model for the tissue factor pathway to thrombin. II. A mathematical simulation. J Biol Chem 269, 
23367-23373, (1994). 
11
 An, G. Agent-based computer simulation and sirs: building a bridge between basic science and clinical trials. Shock 16, 266-273, 
(2001). 
12
 Bankes, SC. Agent-based modeling: A revolution? PNAS 99, 7199-7200, (2002). 
13
 Bonabeau, E. Agent-based modeling: Methods and techniques for simulating human systems. PNAS 99, 7280-7287, (2002). 
14
 Rider, RE. Aspects of Ulam: From Cardinals to Chaos. Science 246, 134-, (1989). 
15
 Wolfram, S. Cellular Automata and Complexity: Collected Papers.  (Westview Press, 1994). 
16
 Wilensky, U.  (Center for Connected Learning and Computer-Based Modeling, Northwestern University, Evanston, IL, 1999). 
17 van `t Veer, C et al. Inhibitory Mechanism of the Protein C Pathway on Tissue Factor-induced Thrombin Generation. Synergistic 
Effect in Combination with Tissue Factor Pathway Inhibitor. J. Biol. Chem. 272, 7983-7994, (1997). 
18
 van `t Veer, C & Mann, KG. Regulation of Tissue Factor Initiated Thrombin Generation by the Stoichiometric Inhibitors Tissue 
Factor Pathway Inhibitor, Antithrombin-III, and Heparin Cofactor-II. J. Biol. Chem. 272, 4367-4377, (1997). 
19
 Krishnaswamy, S. The interaction of human factor VIIa with tissue factor. J. Biol. Chem. 267, 23696-23706, (1992). 
20
 O'Brien, DP et al. Surface plasmon resonance studies of the interaction between factor VII and tissue factor. Demonstration of 
defective tissue factor binding in a variant FVII molecule (FVII-R79Q). Biochemistry 33, 14162-14169, (1994). 
21
 Shobe, J et al. Macromolecular Substrate Affinity for the Tissue Factor-Factor VIIa Complex Is Independent of Scissile Bond 
Docking. J. Biol. Chem. 274, 24171-24175, (1999). 
22
 Butenas, S & Mann, KG. Kinetics of human factor VII activation. Biochemistry 35, 1904-1910, (1996). 
23
 Baugh, RJ, Broze, GJ, Jr. & Krishnaswamy, S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway 
inhibitor. J Biol Chem 273, 4378-4386, (1998). 
24
 Baugh, RJ et al. Exosite interactions determine the affinity of factor X for the extrinsic Xase complex. J Biol Chem 275, 28826-
28833, (2000). 
25
 Baugh, RJ & Krishnaswamy, S. Role of the activation peptide domain in human factor X activation by the extrinsic Xase 
complex. J Biol Chem 271, 16126-16134, (1996). 
26
 Bergum, PW et al. Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-
tissue factor complex by recombinant nematode anticoagulant protein c2. J Biol Chem 276, 10063-10071, (2001). 
27
 Bom, VJ et al. Extrinsic activation of human coagulation factors IX and X on the endothelial surface. Thromb Haemost 66, 283-
291, (1991). 
28
 de Moerloose, P, Bounameaux, HR & Mannucci, PM. Screening test for thrombophilic patients: which tests, for which patient, 
by whom, when, and why? Semin Thromb Hemost 24, 321-327, (1998). 
29
 Rawala-Sheikh, R et al. Kinetics of coagulation factor X activation by platelet-bound factor IXa. Biochemistry 29, 2606-2611, 
(1990). 
30
 Lollar, P, Parker, ET & Fay, PJ. Coagulant properties of hybrid human/porcine factor VIII molecules. J Biol Chem 267, 23652-
23657, (1992). 
31
 Fay, PJ & Smudzin, TM. Characterization of the interaction between the A2 subunit and A1/A3-C1-C2 dimer in human factor 
VIIIa. J Biol Chem 267, 13246-13250, (1992). 
120
32
 Fay, PJ et al. Model for the factor VIIIa-dependent decay of the intrinsic factor Xase. Role of subunit dissociation and factor IXa-
catalyzed proteolysis. J Biol Chem 271, 6027-6032, (1996). 
33
 Lawson, JH et al. Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. J Biol Chem 268, 767-770, 
(1993). 
34
 Rosing, J et al. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 255, 274-283, (1980). 
35
 Hill-Eubanks, DC & Lollar, P. von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain. 
J Biol Chem 265, 17854-17858, (1990). 
36
 Monkovic, DD & Tracy, PB. Activation of human factor V by factor Xa and thrombin. Biochemistry 29, 1118-1128, (1990). 
37
 Jesty, J, Wun, TC & Lorenz, A. Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue 
factor pathway inhibitor in the presence and absence of heparin. Biochemistry 33, 12686-12694, (1994). 
38
 Chuang, YJ et al. Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center 
loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin. J Biol Chem 276, 
14961-14971, (2001). 
39
 Jordan, RE et al. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J 
Biol Chem 255, 10081-10090, (1980). 
40
 Schoen, P & Lindhout, T. The in situ inhibition of prothrombinase-formed human alpha-thrombin and meizothrombin(des F1) by 
antithrombin III and heparin. J Biol Chem 262, 11268-11274, (1987). 
 
 
 
121
 Future Directions 
The next step in the progression of our coagulation model is to simulate the in vivo environment.  
Expansion of the model will require the addition of blood flow, endothelial cells, white blood 
cells, platelets, and the full complement of coagulation proteins.  Such a model will provide 
insight into complex disease processes that are impossible to obtain using laboratory techniques.  
Computational systems biology allows the design and implementation of experiments that would 
be unethical and dangerous in the clinical setting; instead, creation of previously unavailable 
diagnostic and therapeutic strategies becomes possible.   
 
The time required to update the model is one disadvantage of ABMS as it is computationally 
expensive for large systems with many elements.  Not only does this necessitate long 
development times, but limits the use of the model to offline situations.  Conversion of the model 
into other platforms may provide significantly decrease the time required to run simulations and 
increase its utility as a clinical tool.   For example, the model can be moved to an alternate 
ABMS platform (I.E. Repast) with an expected halving of the execution time.  Ultimately, 
conversion of the model into a format that can be run on graphical processing units (GPU) may 
allow significant decreases in execution time (on the order of 100x) that could allow simulations 
to be run at a patient’s bedside in real-time. 
 
TIC: A Computational Model of In Vivo Trauma Induced Coagulopathy* 
Objective: The PULSE initiative identified prevention of diffuse coagulopathies to be a priority 
in resuscitation science. Trauma Induced Coagulation (TIC) is a significant complication of 
* Presented at the 2008 American Heart Association Annual Meeting, and was awarded the 
young investigator award. 
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trauma involving the complex nonlinear interplay of the coagulation and inflammation system 
(CIS). Its complexity poses significant challenges for systematic clinical study.  Modeling via 
computational approaches may prove to be a valuable adjunct. We developed a model of TIC 
using a 2-D Agent Based Model (ABM).  
 
Methods: A 2-D particle system was developed in which particles move and interact on a 
discrete spatial grid composed of ‘cells’. The particles of the system are cells (endothelial, WBC, 
platelets), reactants, enzymes, and reaction products. The number of ‘cells’ used in the 
simulations is 1,000,000 with a coagulation factor density of 16%. The particles’ actions are 
determined by a set of rules derived from coagulation kinetics and cell behaviors. The system is 
designed to model a blood vessel in vivo including blood flow. The model is perturbed by 
alterations in systemic variables (temperature, pH, coagulation factor concentration, 
oxygenation).  
 
Results: The effects of temperature, pH, and coagulation factor dilution were synergistic on the 
model resulting in increased INR values ranging from 1.5 to 7.76. A state of anti-coagulation and 
hyperfibrinolysis existed independent of temperature and pH. Endothelial cell activation from 
hypovolemia resulted in the increased expression of TM, TFPI, and tPA with a concomitant 
decrease in PAI. This resulted in a state of anticoagulation from the diversion of thrombin to the 
activation of PC (by binding to thrombin) combined with increased TFPI. Increased levels of 
tPA combined with decreases in PAI result in a state of hyperfibrinolysis that dissolves any clot 
formed in the anti-coagulation environment.  
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Conclusion: The simulation indicates that the effects of trauma on the CIS can be readily 
simulated.  The ABM successfully modeled TIC seen in vivo due to endothelial cell activation 
from hypoperfusion as supported by the literature. The ABM will be used to target mediator 
levels for clinical verification as well as to develop preclinical and clinical testing of therapies 
that may modulate the CIS to enhance outcomes. 
 
DIC: A Computational Analysis of the Coagulopathy Associated with Disseminated 
Intravascular Coagulopathy* 
 
Objective: The PULSE initiative identified prevention of diffuse coagulopathies to be a priority 
in resuscitation science. Disseminated Intravascular Coagulopathy (DIC) is a significant 
complication of diseases such as sepsis and cancer.  DIC involves the complex nonlinear 
interplay of the coagulation, fibrinolytic, and inflammatory systems (CIF). Its complexity poses a 
significant challenge for systematic clinical study; thus, modeling via computational approaches 
may prove to be a valuable adjunct. We developed a model of DIC using a 2-D Agent Based 
Model (ABM) implemented in the Netlogo modeling platform.  
 
Methods: A 2-D particle system was developed in which particles move and interact on a 
discrete spatial grid composed of ‘cells’. The particles of the system are cells (endothelial, WBC, 
platelets), cytokines, reactants, enzymes, and reaction products. The number of ‘cells’ used in the 
simulations is 5041 with approximately 500,000 agents. The agents’ actions are determined by a 
set of rules derived from coagulation kinetics and cell behaviors. The system is designed to 
model a blood vessel in vivo including blood flow.  The grid is in the shape of a rectangle.  The 
* Presented at the 2009 Annual SwarmFest. 
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sides of the rectangle represent endothelial cells and allow agents to interact with the endothelial 
cells or bounce off the walls.  The ends are empty and allow the loss and introduction of agents.  
Blood flow is simulated by pulsatile movement of the particles through the system.  The model is 
perturbed by the introduction of elevated levels of TNF-α in order to simulate the systemic 
inflammatory response from an insult such as sepsis.  
 
Results: The simulation represents the formation of DIC due to elevated levels of TNF-α and 
subsequent activation of the inflammatory system.  The activation of the coagulation system 
leads to the formation of microvasculature clot formation and a consumptive coagulopathy that 
results in the impairment of hemostasis.  Table 1 demonstrates the alteration in the plasma levels 
of Antithrombin III (AT), Fibrinogen (F), platelet (plt), and Fibrin Split Products (FSP).  As can 
be expected, the levels of AT, F and plts decrease as they are consumed by the systemic 
activation of the coagulation system, and the levels of FSP continue to increase as the clot is 
continually dissolved by the fibrinolytic system.   
 
Conclusion: The simulation indicates that the effects of systemic inflammation on the CIF can 
be readily simulated using ABM.  The ABM effectively modeled DIC as the end product of 
elevated cytokine levels as may be seen in sepsis.  The demonstrated parameters and resultant 
coagulopathy are consistent with clinical DIC found in the literature. The goal in creating an 
ABM of DIC is to develop preclinical and clinical testing of therapies that may modulate the CIF 
to enhance patient outcomes. 
 
Time (h) AT (µM) Fibrinogen (µM)  Platelet (x 10
9
) FSP(µg/mL) 
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0 4.50 88.20 300 0.0 
1 4.37 83.74 291 0.3 
4 3.65 74.91 271 2.7 
8 2.74 64.29 227 6.0 
12 1.80 29.63 39 33.5 
16 1.07 22.06 11 37.5 
Table 1: Plasma levels of AT, F, Plt, and FSP in DIC 
 
Cardiac Arrest: A Computational Model of the Effect of Cardiac Arrest on the 
Coagulation System* 
 
Objective: The PULSE initiative identified prevention of diffuse coagulopathies to be a priority 
in resuscitation science. Coagulopathy is a potential significant complication of cardiac arrest 
that involves the complex nonlinear interplay of the coagulation and inflammation system (CIS). 
This complexity has made it difficult to study it in an integrative fashion at the microvessel level 
in cardiac arrest. We developed a 2-D Agent Based Model (ABM) to begin to better understand 
the CIS in cardiac arrest. 
 
Methods: The ABM utilizes a 2-D particle system. Particles move and interact on a discrete 
spatial grid. The particles of the system are the cells, reactants, enzymes, and reaction products. 
The system is designed to model a blood vessel in vivo. The grid is in the shape of a rectangle. 
The sides of the rectangle represent endothelial cells; particles are capable of interacting with the 
endothelial cells. In a steady state, blood flow was suddenly discontinued for 20 minutes 
followed by return of spontaneous circulation (ROSC) for another 20 minutes. The levels of 
circulating coagulation factors and their products and function were continually monitored.  
* Presented at the 2008 American Heart Association Annual Meeting. 
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 Results: After 20 minutes of no flow, we observed a state of hypercoagulability, impaired 
fibrinolysis, and systemic microthrombi formation consistent with post-arrest clinical studies in 
the literature. Endothelial cell response to hypoxia results in elevated levels of TAT and fibrin 
monomers consistent with activation of the coagulation system. Concomitant lack of D-dimer 
and FSPs demonstrated the decreased expression of TM, TFPI, and tPA. Following ROSC, the 
activation of the anticoagulation system and pro-inflammatory mediators resulted in a disruption 
of the equilibrium between the coagulation, anti-coagulation, fibrinolytic and inflammatory 
systems consistent with a clinical state of low grade DIC.  This was also consistent with the 
literature.  
 
Conclusions: The ABM model simulates the effects of cardiac arrest on the CIS and may be 
useful for studying arrest induced CIS changes as well as what affects various interventions such 
as hypothermia may have.  Data obtained will be used to target mediator levels for verification as 
well as to design studies that may modulate the CIS to improve outcomes.  
 
GPU based: Utilizing GPU Computing to Analyze Complex Biological Systems* 
The coagulation system (CS) is a complex, inter-connected biological system with major 
physiological and pathological roles. The CS may be viewed as a complex adaptive system,
 
through which multiple feedback and feed-forward loops link its individual components.  Non-
linear relationships between the numerous coagulation factors render the study of this biology at 
a molecular and cellular level nearly impossible.  We have employed an Agent Based Modeling 
Simulation (ABMS) in our current approach to the analysis of the CS. One of the most 
* Submitted to the 2010 ACM International Conference on Bioinformatics and Computational 
Biology 
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significant drawbacks to using ABMS is the computational expense associated with large 
systems. 
 
To date, our efforts to successfully model the CS have been stymied by the time required to run 
simulations.  The large number of elements (on the order of 10
6
) requires days to weeks to run 
basic simulations.  We hypothesized that conversion of the model into other platforms may 
significantly decrease this time. We present a comparison of the run-times of 4 ABMS models: 1 
& 2) common platforms Netlogo and Repast; 3)  C program designed to run on a single 
processor and 4) C program designed to utilize the parallel architecture of the Graphics 
Processing Unit (GPU).  As expected, it is observed that GPU-based execution affords 
significant improvement (on the order 10
3
) over the conventional ABMS platforms on the 
runtimes of our complex CS model.   
 
GPU computing provides the opportunity to obtain near supercomputer performance on a 
desktop computer. The use of this virtual supercomputer can fuel complex systems analysis 
without the need for costly high performance computing resources.  Our results indicate that 
complex models of the human CS can be implemented using GPU based computing with 
significant gains in performance.  The use of such models will allow the creation of rapid and 
inexpensive virtual laboratories that can be used to generate and test hypotheses and provide 
clinical tools to design and test novel therapeutic strategies.   
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Summary 
By definition, a complex system exhibits emergent and self organized behaviors. They  typically 
involve many heterogeneous components that interact in a nonlinear manner usually involving 
feedforward and feedback loops which are used to amplify or dampen signals.  Complex systems 
are bound by their components.  Through production and utilization of information from their 
internal and external environments, these components collectively give rise to complex, 
changing patterns and behaviors.  As a result, unique properties emerge.  These properties lead to 
a common definition of complex systems:  a large number of simple components with simple 
behavior that gives rise to complex collective behavior despite the lack of an overlying controller 
and sophisticated information processing and adaptation.   
 
The complex behavior that arises from such systems is called emergent behaviors.  If the 
organized behavior occurs despite the lack of a controller, the system is labeled “self-organizing” 
Complex systems are ubiquitous through the natural world.  Analysis of complex systems 
requires interdisciplinary measures to describe these sophisticated systems.  Computational 
modeling offers an attractive in silico approach to such analysis. 
 
Computational systems biology is a rapidly growing field that provides tools to analyze and 
understand dynamic evolutionary networks.  A major advantage of this approach is its rapid, real 
time analysis of overlapping biological systems, each of which can be a highly coordinated 
independent network interacting with other networks in the group at one or more branch points. 
These independent networks can be thought of as small molecular machines, which work co-
operatively to form a large, multi-component molecular machine producing one or more 
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physiological responses. Understanding the mechanism and co-operativity of these networks as 
well as predicting the physiological response to appropriate pharmaceutical agents is an 
extremely difficult and intricate task. Advanced systems biology techniques, e.g. computational 
technology, hold major promise in achieving this goal and consequently may be extremely useful 
in understanding patho-physiological conditions and their treatment.   
 
In order to develop useful integrative systems biology approaches, computational tools integrate 
complexity theory to predict responses of relevant processes to interventions.  Mathematical 
models represent one such method. The failure of animal models to accurately predict the 
usefulness of therapies and the difficulty of enrolling large numbers of human subjects in studies 
has been a major roadblock in the study of complex diseases. Mathematical models offer a non-
invasive intermediary step that allows hypothesis and therapies to be tested prior to clinical 
studies. Thus, an in silico model would potentially increase the success rate of clinical trials or 
aid in designing more appropriate animal studies. Manipulation of the model would then provide 
direction to the subsequent methodologies necessary to take the next steps in discovery. These 
animal or clinical studies would then in turn, validate the model. 
 
Ideally, a well-constructed computational model will offer a rapid and inexpensive virtual 
laboratory to simulate the effects of biological hypotheses prior to testing these theories in vitro 
or in vivo[77]o.  Accurate predictions by any model, from cell cultures to in vivo animal models 
to mathematical models, are dependent on the accuracy of the relation between the model and the 
corresponding real-world process. They are highly dependent on certain data imputations that are 
derived from animal data, clinical results, or assumptions based on observations or general 
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agreements within the community studying the disease.  Such models require extensive 
validation; however, it will eventually provide insight into processes that are initially difficult to 
observe in an intact system. Thus, a successful computational model will not only fill the gaps in 
our knowledge, it will also identify previously unrecognized gaps as well. 
 
In addition to the benefits associated with theoretical advances, simulations provide clinical tools 
to design and test novel therapeutic strategies, while affording opportunities to predict adverse 
events during drug development.  Bedside simulations will allow personalized medicine in that 
replacement factor concentrations can be calculated for individual hemophiliac patients, heparin 
doses can be titrated, etc…  Other applications of the model include discovery of new mediators, 
understanding of proximal and distal effects of interactions between systems, discovery of new 
diagnostic and therapeutic options, and development of new software and algorithms for 
simulation.    
 
Normal wound healing is a carefully choreographed process that results in a mature scar, which 
restores the anatomic and functional integrity of the dermis[25]. The process is divided into an 
orderly progression of individual phases. The hemostatic phase is controlled by platelets, which 
ensure wound stabilization and recruits inflammatory cells into the wounded tissue. The 
inflammatory phase, which is initially dominated by neutrophils and subsequently by 
macrophages, prepares the wound bed by killing bacteria and removing devitalized tissue as well 
as recruiting fibroblasts. The proliferative phase is characterized by fibroblasts laying down a 
provisional ECM matrix. The remodeling phase is a balance of collagen synthesis and 
degradation that results in a mature scar that maximizes wound tensile strength.  The complexity 
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of acute wounds have stymied clinical investigators.  Computational biology shows promise in 
providing an alternative avenue of study for wound healing. 
 
We have modified an ODE model of the acute systemic response to inflammation a soft tissue 
injury.  Our model includes factors such as bacterial contamination and wound oxygenation.  
Assuming normal conditions, our model predicts the typical progression of healing behavior for 
a wound.  The ODE model was also able to successfully simulate the impairment in wound 
healing found in a hypoxic wound environment and a contaminated wound. For example, under 
hypoxic conditions, we observe a non-healing wound where the damage persists despite the 
absence of pathogens. With extremely low levels of oxygen our model predicts a chronic 
infection where the wound does not heal and pathogens persist in the wound.  Both of these 
states are well documented clinically. 
 
We also examined the situation of elevated and depressed fibroblasts mortality rates. Clinically, 
instances of elevated fibroblast mortality are seen in diabetic and elderly patients. We observed 
non-healing wounds in the context of high rates of fibroblast mortality. Additionally, a scenario 
of moderately low fibroblast mortality and high initial pathogen levels predicts the state of 
chronic infection. Finally, we examined the case where fibroblast production is either impaired 
or enhanced. Impaired fibroblast production results in a non-healing state; however with an 
increase in production, wounds heal at notably faster rates.  This provides a framework from 
which to test a new hypothesis in a living model, i.e. improve fibroblast production in an effort to 
increase wound healing rates. 
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Our model successfully simulated results typical of hypoxic wound environments with 
significant bacterial contamination. Though most of our results are not overly surprising, we are 
satisfied and encouraged that our model is qualitatively accurate in its predictions of real 
systems.  This provides some level of model calibration. Translation of our model to the level of 
clinical relevance will require an enormous number of important variables both at the local and 
systemic levels. We are now in the process of examining systemic mediators and their effects on 
healing at the local environment. This includes hormonal differences thus taking into account 
gender differences and the effects of systemic inflammation.   
 
Another difficult clinical problem is that of diseases associated with coagulation and fibrinolysis.  
Coagulation is a complex process by which blood forms solid clots.  It is an important part of 
hemostasis defined as the cessation of blood loss from a damaged vessel.  A damaged blood 
vessel wall is covered by a platelet- and fibrin-containing clot to stop bleeding.  Coagulation is 
initiated almost instantly after an injury to the blood vessel damages the endothelium (lining of 
the vessel).  Fibrinolysis is a complex process by which pre-formed clot is proteolitically 
degraded once the underlying endothelial injury has been repaired.  The CF systems interact 
strongly at the molecular and cellular level; they thereby operating as a coherently linked system, 
to generate several pathological and physiological responses. The highly complex CF system 
presents a challenging problem of identifying the root cause of many known coagulation defects. 
To date the contribution of each system as a part of the network has not been attempted.  
Furthermore, the difficulties in studying a system that has the following properties: 
nonstationarity, spatial heterogeneity, and blood flow.  The CF system also can be defined as a 
complex system: 1) large number of heterogenous components (zymogens, enzymes, cofactors, 
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inhibitors, membranes, and cells), 2) no overlying controller (the CF reactions are all local and 
based on molecular interactions), 3) non-linear (the biochemical reactions among the 
components are all non-linear), and 4) emergence (threshold effects for thrombin generation, 
localized clot formation, and delayed clot lysis).  Given the difficulties associated with the study 
of the CF system, the study of such a complex system may benefit from computational analysis.   
 
We have developed an ABMS of the CF cascade that allows systematic evaluation of each of its 
components – individually and as a complex entity.  The model allows a comprehensive analysis 
of the CF cascade that provides insight into understanding and predicting the pathophysiologic 
responses arising from variations in molecular and cellular components.  ABMS allows a real 
time analysis of the CF systems that is difficult if not impossible to obtain through in vivo 
experiments.  Additionally, ABMS provides an opportunity to understand the complex interplay 
among the various subsystems at any point in time.  Reductionist in vitro experimental 
techniques have allowed a detailed understanding of the individual chemical reactions involved 
in the process of coagulation.  ABMS represents a non-reductionist approach of studying the 
biologic process as a whole, while retaining the information at an individual level.  The 
information obtained by studying the individual reactions is used as the basis for the rules 
governing the updating of the ABMS. The advantages of ABMS include the ability to simulate 
the non-linear aspects of the coagulation system.  As the agents are able to change state based on 
their environment, the model adapts and accounts for changes such as dearth/excess of 
coagulation inhibitors, absence of factors, or therapeutic interventions.  The time required to 
update the model is one disadvantage of ABMS as it is computationally expensive for large 
systems with many elements; however a specific advantage of this model is its ability to allow 
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for the addition of newly discovered mediators, which can impact upon both coagulation and 
inflammation. More importantly, the model has a high probability of exhibiting emergence in 
which its outputs produce unanticipated results, which can then be biologically confirmed. Such 
properties are particularly useful in the discovery of diagnostic and therapeutic interventions. 
Comprehensive modeling of the traditional coagulation cascade allows virtual experimentation 
of the effects of local and systemic injury on coagulation.  
 
The in vitro CF system can be readily simulated using ABMS.  Our ABMS approach 
successfully reproduces the initiation, propagation, and termination of thrombin formation in 
vitro. Furthermore, the ABMS was able to simulate the threshold effect of thrombin formation 
resultant from the synergistic relationship between physiologic concentrations of coagulation 
inhibitors.    This suppression of thrombin is the likely mechanism behind localization of the 
hemostasis response.  The mechanism demonstrated herein provides the rationale for localized 
formation of a blood clot at the site of endothelial injury as opposed to a systemic vascular 
thrombotic response.  Presumably, the thrombin concentrations upstream and downstream of the 
endothelial injury fail to reach self sustaining levels due to the synergistic effects of AT, TFPI, 
and aPC.  A possible therapeutic strategy of manipulating coagulation inhibitors for the treatment 
of diseases involving the systemic activation of the CS, such as TIC, DIC, coagulopathy 
associated with cardiac arrest, etc…, is suggested by the findings in this paper.  The model also 
successfully simulated aPTT and PT times at normal physiologic conditions, abnormal 
physiologic conditions (hemophilia B and AT-H binding defect), and after pharmaceutical 
interventions (warfarin and heparin).  The non-linearities of the CF system were captured using 
this ABMS.  The ability to generate results similar to those obtained experimentally has been 
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demonstrated.  The error bars associated with the data are unique to ABMS and provide the 
ability to simulate experiments and clinical trials. 
 
The next step in the progression of our coagulation model is to simulate the in vivo environment.  
Expansion of the model will require the addition of blood flow, endothelial cells, white blood 
cells, platelets, and the full complement of coagulation proteins.  Such a model will provide 
insight into complex disease processes that are impossible to obtain using laboratory techniques.  
Computational systems biology allows the design and implementation of experiments that would 
be unethical and dangerous in the clinical setting; instead, creation of previously unavailable 
diagnostic and therapeutic strategies becomes possible.   
 
The time required to update the model is one disadvantage of ABMS as it is computationally 
expensive for large systems with many elements.  Conversion of the model into other platforms 
may provide significantly decrease the time required to run simulations.   For example, the 
model can be moved to an alternate ABMS platform (i.e. Repast) with an expected halving of the 
execution time.  Ultimately, conversion of the model into a format that can be run on graphical 
processing units (GPU) may allow significant decreases in execution time (on the order of 100x) 
that could allow simulations to be run at a patient’s bedside in real-time. 
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